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1.1 Bone grafts 
According to the 3rd edition report of The Burden of Musculoskeletal Diseases in the 
United States, the number of people who received care after suffering bone fractures 
rose to more than 23 million [1]. As fracture incidences have been shown to have a 
bimodal distribution with a high rate for elderly people [2], an increase in fracture 
prevalence in an ever-aging society can be expected in the future. While most fractures 
heal within 3–8 weeks [3], about 5–10% of fractures end in non-unions [4], which 
together with infected non-unions, high-energy injuries and bone loss due to i.e. tumor 
resection cause critical bone defects [5]. The treatment of bone defects is challenging 
for the attending surgeon, and in many cases, bone grafts are required. While 
autologous bone grafting is currently still considered the gold standard [6,7], some 
limitations are associated with autologous grafting, such as risk of infections, additional 
surgical sites and limited bone supply [8].  
Allografts and xenografts present viable alternatives to autografts as they solve the 
problem of limited autologous bone supply and do not require an additional surgical 
site for graft harvesting [9]. However, allogenic and xenogenic grafting can carry the 
risk of infection [10] and may induce an immunological reaction in the graft recipient 
[11]. Thus, a successful usage of allografts and xenografts in vivo requires a thorough 
removal of immune response eliciting material, such as bone marrow content or 
potential pathogens [12]. This is usually achieved by decellularizing the bone graft 
using a combination of chemical substances (Triton X-100, sodium dodecyl sulfate, 
hydrogen peroxide), enzymes (DNase, trypsin) and physical treatment (centrifugation, 
sonication, temperature treatment).  
While decellularization may be viewed as the central step in graft processing, donor 
selection [13] and graft harvesting [14] have also been shown to exert an influence on 
the graft’s properties. Properties of the bone graft such as surface area, surface 
structure, chemical composition and mechanical stability may be altered by the 
processing of the graft [15–17] and may influence the implantation in vivo or the growth 
of bone forming cells such as mesenchymal stem cells, for instance. Hence, special 
attention must be paid in terms of processing. 
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1.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are adult human stem cells [18] which were first 
described by Friedenstein et al. in the 1960s and 1970s [19]. Originally, they were 
isolated from bone tissue [20] and showed a multilineage potential. While MSCs 
account for ∼	0.01–0.001% of all cells in the bone marrow [21], they have also been 
successfully isolated from a variety of tissues, such as adipose tissue [22,23], 
peripheral blood [24], dental tissue [25], synovial fluid [26], amniotic fluid [27], 
Wharton’s jelly [28] and from the placenta [29]. However, some authors suggest that 
they can be found in all organs and tissues [30].  
MSCs have traditionally been described with a trilineage potential, able to differentiate 
into adipocytes, chondrocytes and osteoblasts. However, more recent publications 
describe an even greater differentiation potential of MSCs, also being able to 
differentiate into tendon [31], muscle [32], cardiomyocytes, pancreatic cells, 
hepatocytes and neuronal cells, depending on the tissue of isolation [18,33]. 
While the physiological functions of MSCs in situ are not yet fully comprehended, 
MSCs have been found to contribute to the formation of hematopoietic 
microenvironments, modulate the activity of immune cells and to regulate cell traffic 
[34].  
 
1.2.1 Defining mesenchymal stem cells 
One of the challenges presented when working with MSCs is the heterogeneous 
nature of MSC cultures. Different laboratories often use different isolation methods for 
MSCs, usually based on their ability to readily adhere to plastic. This renders MSC 
cultures heterogeneous, thus making it difficult to compare study outcomes conducted 
with MSCs across different laboratories. In order to address this problem, the 
International Society for Cellular Therapy published a statement in which they propose 
minimal criteria for the definition of mesenchymal stem cells. According to this 
statement, MSCs must (1) exhibit adherence to plastic, (2) display certain cell surface 
markers, such as CD105, CD 73 and CD90 and lack other markers such as CD45, 
CD34, CD14, CD19 and HLA-DR surface molecules. Additionally, (3) MSCs must 
show the potential to differentiate in vitro into adipocytes, chondrocytes and 
osteoblasts [35].  
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1.2.2 Areas of application of mesenchymal stem cells 
To this date, several clinical studies have been conducted with mesenchymal stem 
cells which have underlined their regenerative potential in a variety of applications. A 
randomized, double-blinded, placebo-controlled, dose escalation study showed a 
significant improvement in the left ventricular ejection fractions of patients after 
suffering from myocardial infarction when treated with intracoronarily delivered MSCs 
compared to the placebo group [36]. Phase 1, 2 and 3 trials are currently ongoing for 
further validation of MSC treatment for cardiac regeneration [37]. Additionally, MSCs 
have also shown potential to support renal tissue after acute kidney infarction [38,39].  
Some positive effects could be observed in patients suffering from spinal cord injury 
when treated with MSCs, however, what effect MSCs have on motor neuron function 
is still inconclusive [40]. Furthermore, MSCs also show promising results in the 
advancement of treatment strategies for patients with type I [41] and II [42] diabetes.  
However, they have been extensively researched and used in the area of bone and 
cartilage repair. In patients suffering from osteoarthritis, treatment with MSCs lead to 
an improvement in pain and symptoms [43,44], while the generation of large sized 
cartilage in vitro has recently been accomplished using MSCs [45], creating the 
possibility to treat larger sized cartilage defects. Patients suffering from osteogenesis 
imperfecta, a genetically inherited condition resulting in brittle bones, have also profited 
from allogenic bone marrow transplants as the receival of new mesenchymal 
progenitors improved the condition [46]. Avascular femoral head osteonecrosis is 
another condition in which MSCs haven shown to slow progression of the disease and 
additionally avoid subsequent femoral head collapse and joint replacement [47,48]. 
Fractures resulting in atrophic non-unions, despite adequate surgical intervention have 
been successfully treated using autologous MSCs [49].  
Likewise, MSCs show promising results concerning the treatment of critical-size bone 
defect [50]. In vivo studies have repeatedly shown an acceleration in bone repair when 
bone grafts were loaded with MSCs prior to implantation [51,52] and several authors 




1.2.3 Immunomodulatory and immune-evasive properties of 
mesenchymal stem cells 
Another well-described characteristic of MSCs is their immunomodulatory and 
immuno-evasive property in vitro. When cultured with other cells, MSCs secrete 
soluble factors that have been shown to possess an immunosuppressive activity [55]. 
Additionally, MSCs have been shown to express no MHC class II and only low levels 
of MCH class I [56]. Clinical trials using allogenic MSCs have been conducted with 
success [36], thus raising the question if the usage of autogenic MSCs is just as 
effective as they have to be expanded in vitro 4–6 weeks prior to usage. However, 
more recent publications question the traditional view on immunosuppression and 
immuno-evasion. Several in vivo studies have shown a difference in study outcomes 
based on the usage of allogenic and autogenic MSCs [57,58]. It is proposed that this 
effect is observed when MSCs mature in the donor to more differentiated cells, which 
in turn express higher levels of MHC I and II [59], thus losing their immuno-privileged 
status.  
The immunomodulatory properties of MSCs are also used as an explanation for study 
outcomes involving the treatment of diseases caused by underlying immunological 
issues. As such, beneficial effects of MSC treatment have been found in diseases such 
as Crohn’s disease [60], multiple sclerosis [61], amyotrophic lateral sclerosis [62] and 
steroid resistant graft versus host disease [63].  
 
1.2.4 Role of mesenchymal stem cells in bone formation 
Mesenchymal stem cells also play a pivotal role during bone formation after bone 
fractures. After a fracture, blood vessels rupture and a hematoma is formed, preventing 
further loss of blood and of bioactive factors [64]. Initial fracture site environment is 
characterized by inflammation and hypoxia, promoting and signaling immune cells 
participating in the healing process [65] and bone progenitors are recruited to the site 
of fracture around day 3 [66]. While this migration to the fracture site is not yet 
completely understood and several factors are involved, [67] the stromal cell-derived 
factor 1 (SDF-1)/CXCL12 CXCR4 chemotactic axis is the most researched mechanism 
in this context [68,69]. Inhibition of this pathway significantly alters fracture repair [70]. 
MSCs migrate to the fracture site from several niches such as the periosteum, 
endosteum, bone marrow [71] and the perivascular niche [72]. The occurrence of 
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MSCs in the perivascular niche is not limited to bone tissue but mesenchymal stem 
cells have been shown to be present in the perivascular niche throughout the entire 
body [73]. This might explain why authors establish that MSCs have been found in 
various organs such as the spleen, kidney, liver, lungs, pancreas, brain, aorta and the 
vena cava [30,74]. Circulating MSCs have also been found, however, it is not clear yet 
to what extent they are recruited in fracture healing [75,76]. After the fracture 
hematoma has formed, SDF-1 levels rise [77], which in turn attracts CXCR4 
expressing cells. Since the SDF-1 gene is regulated by the hypoxia-inducible factor-1 
(HIF-1) [78], hypoxia in the fracture hematoma contributes to chemotactic factor 
secretion and cell migration. Additionally, the hypoxic environment induces the 
secretion of vascular endothelial growth factor (VEGF) [79], stimulating the formation 
of new blood vessels which is critical for new bone formation [80]. MSCs have shown 
to significantly contribute to VEGF secretion [81]. Following migration, MSCs 
differentiate into osteogenic cells and contribute to the formation of bone substance 
[82].  
 
1.2.5 Osteogenic differentiation of mesenchymal stem cells 
Osteogenic differentiation of MSCs is a two-step process: (1) lineage commitment and 
(2) maturation [83]. The process of lineage commitment is complex, controlled by 
multiple factors. Ascorbic acid has been found to increase extracellular matrix (ECM) 
secretion followed by an upregulation of osteogenic markers such as alkaline 
phosphatase (ALP) and osteocalcin [84]. Dexamethasone, on the other hand, 
increased cell proliferation and ALP activity [85] while β-glycerophosphate provides 
phosphates for mineral deposition [84]. Countless chemical factors are involved in 
osteogenic differentiation, which may act in a synergistical fashion [86]. In addition to 
chemical factors, physical factors such as mechanical forces [87] and biological factors 
such as oxygen supply have also shown to influence differentiation. Hypoxia is known 
to inhibit osteogenic differentiation [88] and to promote MSC to differentiate into 
cartilage [89], thus underlining the importance of vascularization in bone repair. The 
process of osteogenic maturation is usually evaluated using histochemical and 
molecular biological methods. The expression of osteogenic genes such as 
osteopontin, osteonectin, osteocalcin, bone morphogenic protein 2 (BMP-2) and 
alkaline phosphatase can be evaluated using quantitative real-time polymerase chain 
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reaction (qRT-PCR) [90]. Additionally, ALP activity can be quantified by using an 
alkaline phosphatase assay. Following maturation, MSCs start to deposit calcium 
(Ca2+), which is also referred to as the mineralization phase [91]. These calcium 
depositions can be stained with Alizarin Red and evaluated either histologically or 
quantified photocolorimetrically [92].  
 
1.2.6 Alkaline phosphatase  
Alkaline phosphatase is an enzyme found on the outer cell membrane of many different 
cells in the body and exists in different isotypes [93]. The prevalent form found in bone 
tissue is the tissue non-specific alkaline phosphatase (TNAP). While the importance of 
ALP activity in mineralization has been thoroughly established, its exact mechanism is 
not yet completely understood. ALP is transcribed early in the process of osteogenic 
differentiation, rising ∼	11 days after osteogenic induction and decreasing during the 
phase of early mineralization [91]. This points, at least in part, to a role in the early 
phase of mineralization. Early cues on its role and function were derived from patients 
suffering from mutations in the ALP gene. In these patients, severe forms of 
hypophosphatasia could be observed [94]. These findings led to the understanding 
that ALP uses extracellular inorganic pyrophosphates (ePPi) as a substrate and 
hydrolyzes them to inorganic phosphate (Pi), which is a mineralization promoter [95]. 
Thus, ALP provides phosphates for the synthesis of hydroxyapatite, a mineral that 
makes up bone substance and in which calcium and phosphates are stored [96], as 
well as reducing inhibitors for mineralization (ePPi) [95].  
 
1.3 Mesenchymal stem cell applications in conjunction with 
bone grafts 
MSCs have also been studied in depth in conjunction with evaluating bone grafts. Bone 
grafts have shown the potential to influence differentiation of MSCs into the osteogenic 
lineage [97,98]. Furthermore, the combined application of MSCs and bone grafts 
demonstrated enhanced healing properties of large bone defects in vivo after 
implantation [99,100]. However, only a few studies have been conducted that 
investigate the usage of bone grafts loaded with stem cells for the treatment of bone 
defects in human subjects [101–103]. This might be in part due to the efforts involved 
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in harvesting and expanding autologous MSCs and the small number of patients with 
bone defects for whom standard treatment procedures are unsuitable.   
In addition to their ability to produce new bone tissue, the therapeutic potential of MSCs 
has in part been attributed to paracrine effects that MSCs exert via cytokines and 
growth factors [104] on adjacent MSCs and bone tissue upon integration in vivo [105]. 
At the same time, cytokine secretion by MSCs and bone forming cells can be 
influenced by the implant’s properties, such as in CaP containing grafts, being able to 
influence the cells’ secretome towards an osteogenic profile through adenosine 
signaling [106]. Physicochemical properties of the graft have a direct influence on cell 
adherence and cell proliferation of MSCs after seeding onto bone grafts [107–109], 
playing an important role upon application of seeded grafts in vivo. Ideally, the 
processing of bone grafts for tissue engineering applications should decellularize the 
graft completely, inactivate any potential harmful pathogens, maintain biomechanical 
stability and in conjunction with stem cell applications, demonstrate osteoconductive 
or osteoinductive properties combined with high biocompatibility as defined by Williams 
[110]. 
Figure 1. Overview - Mesenchymal stem cell therapy in patients with bone defects. Bone grafts 
are regularly used when treating patients with bone defects. These bone grafts can be harvested 
and processed from xenogenic or allogenic bone sources without the necessity to create an 
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additional surgical site. Mesenchymal stem cells on the other hand can be isolated from various 
tissues such as adipose tissue, bone marrow, blood and the placenta and have shown the 
potential to support healing processes. Recent studies have also shown MSCs to improve graft 
integration and bone regeneration when seeded onto bone grafts prior to implantation. Hence, 
this work focuses on the processing of bone grafts and their in vitro ability to host MSCs, allow 
for adequate proliferation and osteo-induce seeded MSCs.   
 
1.4 Aim and objectives 
Several decellularization methods, such as decellularization based on chemical 
treatment [111], sonication [112] and irradiation [113] have been proposed, yet it 
remains unclear which method results in favorable properties for in vivo use as well as 
favorable reseeding properties in conjunction with MSCs. In this study, we compare 
two decellularization methods adapted from published protocols for bone grafts based 
on chemical treatment [111] or sonication [112]. The effect of each method on the 
graft’s surface texture, composition and decellularization, including bone marrow 
removal, was investigated. Decellularized grafts as well as two commercially available 
grafts, one allograft (Tutoplast®) and one xenograft (Bio-Oss®), were further subjected 
to element analysis and MSC viability assays with extracts derived from the grafts. 
Commercially available grafts were included in this study as additional references for 
standardized graft processing. Self-decellularized grafts as well as commercially 
available grafts were reseeded with MSCs pre-differentiated in osteogenic medium and 
cell adhesion, proliferation and osteogenic activity was assessed in order to compare 
their performance in conjunction with MSCs. 
 
2. Materials and Methods 
 
2.1 Ethical approval 
The use of human tissue and cells was approved by the local ethical advisory board of 
the Medical Faculty of Christian-Albrechts-University in Kiel (Approval number - 





2.2 Comparison of two decellularization approaches 
 
2.2.1 Cutting and preparation of bone cylinders 
Femoral heads were obtained from patients undergoing total hip replacement surgery 
due to coxarthrosis. Criteria for exclusion was necrosis, tumor and infections. Donors 
consisted of five female and five male donors, ranging in age from 42 to 93 years 
(mean 73.2 years, SD ± 18.9 years) and 51 to 80 years (mean 69.8 years, SD ± 14.5 
years), respectively.  
Upon receival, femoral heads were placed in tissue buffer, consisting of GlutaMAXTM 
Medium 199 (Gibco, Darmstadt, Germany), 15% (v/v) fetal bovine serum (FBS) 
(Sigma, Taufkirchen, Germany), 1% (v/v) (100 U/mL / 100 µg/mL) 
Penicillin/Streptomycin (Pen/Strep) (Biochrom, Berlin, Germany), 1% (v/v) (20 µg/mL) 
Ciprofloxacin (Fresenius Kabi, Bad Homburg, Germany), 1% (v/v) (2.5 µg/mL) 
Amphotericin B (Biozol, Eching, Germany) and were then cut into slices using a table 
saw (Proxxon, Wecker, Luxembourg). This was done in conjunction with custom-built 
additions to the table saw. (1) A metal slider to the right of the saw blade served as 
protection (see Figure 2). (2) A custom-built slider with a metal right angle mounted on 
top, which could be adjusted in the direction of the x-axis and the y-axis, served as a 
stabilizer. Femoral heads were cut into discs with a thickness of 5 mm. For this, a 
caliper (Steinle, Ingelfingen, Germany) was used to adjust the distance between the 
saw blade and the cut guide in order to obtain bone discs with the proper thickness. 
After disinfecting all instruments and devices used for bone cutting with 70% (v/v) 
ethanol (Merck, Darmstadt, Germany) and additionally with Biocidal (WAK Chemie 
Medical, Steinbach, Germany), the femoral head was cut along the cut guide in a 
circular movement with a bone holding forceps (Aesculap, Tuttlingen, Germany). This 
was performed under aseptic conditions with the use of sterile surgical gloves 
(CardinalHealth, Dublin, OH, USA).  
Once the bone discs were cut, cylinders with a 6 mm diameter were cut out of the bone 
discs with a trephine hollow drill (Hager & Meisinger, Neuss, Germany) and a laser 
guided bench drilling machine (Bosch, Stuttgart, Germany) (Figure 3). Prior to 
decellularization, bone cylinders were washed in tissue buffer, placed in 48-well plates 
and stored at -80°C without the addition of buffers or liquids. 
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Figure 2. Workplace setup of table saw for manufacturing of bone discs. 
Figure 3. Workplace setup of laser guided bench drilling machine for manufacturing of bone 
cylinders. 
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2.2.2 Decellularization of allografts based on chemical treatment 
After defrosting, chemical decellularization was initiated by 3 freeze/thaw cycles with 
liquid nitrogen. For this, liquid nitrogen was poured into a container and bone cylinders 
were submerged using forceps (Aesculap, Tuttlingen, Germany) and a holding tube 
(Th. Geyer, Renningen, Germany). This was followed by placing the bone grafts in a 
48-well plate and incubating them two times for 24 hours, each in 750 μL 2% (v/v) 
Triton X-100 (Sigma-Aldrich, Taufkirchen, Germany) diluted with phosphate-buffered 
saline (PBS) (Fisher Scientific, Loughborough, UK). All solutions were sterile filtered 
before use. Incubation of bone grafts for decellularization purposes was always 
performed at room temperature on an orbital shaker (Edmung Bühler, Bodelshausen, 
Germany) if not otherwise specified. After treatment with Triton X-100, bone grafts 
were incubated for 24 hours in 750 μL 1% (w/v) sodium dodecyl sulfate (SDS) (Sigma-
Aldrich, Darmstadt, Germany) solution diluted in PBS. Then, they were washed with 
PBS for 30 min on an orbital shaker and incubated with 200 U/mL DNase I (Sigma-
Aldrich, Darmstadt, Germany) solution at 37°C for 12 hours using a dry block incubator 
(Eppendorf, Hamburg, Germany). The procedure was finished by washing the 
allografts three times for 2 hours with PBS on an orbital shaker. Allografts 
decellularized by this protocol are henceforth referred to as chemically processed 
allografts (CPAs). 
 
2.2.3 Decellularization of allografts based on sonication 
Grafts decellularized using sonication are referred to as sonication-based processed 
allografts (SPAs). Bone grafts were defrosted from -80°C, submerged in 1 mL of 
distilled water preheated to 60°C and sonicated for 15 min at 20 kHz with an amplitude 
of 12 microns using a sonication needle (Mk2 sonicator, MSE, London, UK). Allografts 
were then rinsed with PBS until the solution became clear and were then placed in 750 
μL PBS on an orbital shaker for 2 hours at 60°C. This was succeeded by a wash-
centrifuge sequence repeated three times. The sequence consisted in a washing step 
with distilled water at 60°C on an orbital shaker and a centrifugation step at 1850 x g 
for 15 min at room temperature (Heraeus, Hanau, Germany). The first washing step 
was performed for 30 min while the second and third for 10 min. Allografts were then 
sonicated first in 1 mL 3% (v/v) hydrogen peroxide (Sigma-Aldrich, Darmstadt, 
Germany) solution diluted with PBS at 60°C, and then in 1 mL 70% (v/v) ethanol (Th. 
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Geyer, Renningen, Germany) diluted with distilled water at room temperature, both for 
10 min at 20 kHz and with an amplitude of 12 microns. Allografts were then placed in 
distilled water at 60°C for 10 min on an orbital shaker and centrifuged for 15 min at 
1850 x g at room temperature. Decellularization was finished by placing allografts in 
distilled water at room temperature for 30 min on an orbital shaker. After completion of 
either CPA or SPA protocol, allografts were thoroughly washed and stored without the 
addition of buffers or solutions at 4°C until use. 
 
2.2.4 Commercial allografts and xenografts 
Tutoplast® (RTI Surgical, Alachua, FL, USA) and Bio-Oss® (Geistlich, Wolhusen, 
Switzerland) grafts were acquired as cancellous bone blocks from human and bovine 
origin, respectively, and were cut into cylinders with the same dimensions as used for 
decellularization. This was performed using a drilling machine (Dremel, Mt. Prospect, 
USA) with a 6 mm trephine hollow drill. As the cancellous bone blocks measured 1 cm 
in height, the cylinders were cut in half using a scalpel (Feather, Osaka, Japan) and a 
caliper to obtain the same size of the decellularized bone cylinders (6 mm diameter, 5 
mm height) as mentioned above. This process was performed under sterile conditions 
with a laminar flow workbench using sterile surgical gloves and sterile instruments. The 
drilling machine and the hollow drill were disinfected with both 70% (v/v) ethanol and 
Biocidal before use. Bio-Oss® and Tutoplast® are hence forth referred to as Bio-Oss® 
processed xenografts (BPXs) and Tutoplast® processed allografts (TPAs). 
 
2.2.5 Histological examination of decellularized allografts 
Histological examination was performed by fixation of bone cylinders in 4% 
paraformaldehyde (PFA) (Morphisto, Frankfurt am Main, Germany) for 24 hours. 
Samples were embedded in polymethyl methacrylate (PMMA) using a tissue processor 
(Tissue Processor TPC 15, Medite, Burgdorf, Germany). The medium in which the 
samples were embedded (PMMA) consisted of 500 g methyl methacrylate (MMA) 
(Fluka, Neu-Ulm, Germany), 3 g 2,2′-Azobis(2-methylpropionitrile) (Merck, Darmstadt, 
Germany), 100 mL Nonylphenol-polyethylene glycol acetate (Walter-CMP, Kiel, 
Germany) and 5 mL phthalic acid butyl ester (Merck, Darmstadt, Germany). After each 
sample was embedded and completely hardened in a 37°C water bath, they were cut 
using a bandsaw (Metabo, Nur̈tingen, Germany) and then polished with a grinding 
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machine (DP-U4, Struers, Erkrath, Germany) from 500-grit sandpaper to a 4000-grit 
paper. Once the samples were polished to a high gloss polish, they were glued onto a 
plastic microscope slide and the sample was horizontally cut along the slide with a 
thickness of approximately 200 µm using a high precision bandsaw (Exakt, 
Norderstedt, Germany). The thickness of the sample was further reduced to 40-60 µm 
using a high precision grinding machine (Exakt, Norderstedt, Germany) and 
microscope slides with samples were then polished to a high gloss polish.  
Staining was performed by consecutively incubating slides for 2 min with 0.1% (v/v) 
formic acid (Merck, Darmstadt, Germany), 90 min in 20% (v/v) methanol (Merck, 
Darmstadt, Germany) and 2 min in toluidine blue staining solution (Merck, Darmstadt, 
Germany). Solutions were diluted in distilled water, and in-between each step, slides 
were washed in distilled water. Images were taken with EVOS FL Auto 2 Imaging 
System (ThermoFisher Scientific, Bothell USA). 
 
2.2.6 Analysis via scanning electron microscopy 
Specimens were prepared for scanning electron microscopy (SEM) by fixation in 3% 
(v/v) glutaraldehyde (Sigma-Aldrich, Darmstadt, Germany) diluted in PBS. Following 
fixation for 24 hours, samples were treated with ethanol gradients ranging from 50% 
up to 99% (v/v) ethanol. For this, ethanol solutions with 50%, 60%, 70%, 80%, 90%, 
96% and 99% (v/v) ethanol were prepared. Specimens were consecutively incubated 
with each concentration for 2-5 min and then placed on specimen-tables (Agar 
Scientific, Stansted, UK) using carbon adhesive discs (Agar Scientific, Stansted, UK). 
Prior to imaging 3 μL of hexamethyldisilazane (ThermoFisher, Kandel, Germany) were 
applied and samples were gold sputtered with a 10 nm thick layer (SCD 005 Cool 
Sputter Coater, Bal-Tec, Balzers, Lichtenstein). Images were taken with Philips XL 30 
CP SEM (Philips, Amsterdam, Netherlands). 
 
2.2.7 DNA quantification of decellularized allografts 
In order to assess the degree of decellularization, DNA content was quantified from 
CPAs, SPAs, TPAs and BPXs. Additionally, controls that had not been treated other 
than by storing at -80°C were analyzed as a reference. Grafts were placed in 2 mL 
Eppendorf tubes and 1 mL nuclease-free water (Ambion, Carlsbad, CA, USA) was 
added. Then, three freeze/thaw cycles at -80°C and sonication for 30 seconds at 20 
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kHz and with an amplitude of 12 microns using a sonication needle was performed. 
After centrifuging at 2000 x g for 5 min at room temperature, the supernatant was 
transferred, and the total DNA amount quantified with Quant-iT PicoGreen® dsDNA 
assay kit (Molecular probes, Eugene, OR, USA). According to the assay kit manual 
standard DNA solutions were prepared with concentrations ranging from 1 ng/mL to 
2000 ng/mL DNA. After placing 100 µL of buffer solution to each well on a 96-well plate 
(Greiner Bio-One, Kremsmünser, Austria) 28 µL of standard solutions and samples 
solutions were added to the corresponding wells. Then, 72 µL of PicoGreen® solution 
was added which is an ultrasensitive fluorescent nucleic acid stain for quantitating 
double stranded DNA (dsDNA) as it emits fluorescent light when attached to dsDNA 
and excited by 485 nm light. Using standard DNA solutions, a standard curve was 
created from which DNA amount of sample values were calculated. Sample solutions 
were diluted appropriately to fit inside the standard curve.  
DNA quantification for each bone graft material (CPAs, SPAs, TPAs and BPXs) was 
performed for two cylinders from 3 donors in technical triplicates. The DNA amount 
was quantified as mentioned above by fluorescence with a microplate reader (TECAN, 
Maennedorf, Switzerland) at an excitation wavelength of 485 nm and an emission 
wavelength of 535 nm. 
 
2.2.8 Energy-dispersive X-ray spectroscopy 
Energy-dispersive x-ray spectroscopy (EDX) analysis was performed using a Philips 
XL 30 CP SEM. Prior to analysis, samples were sputtered with carbon. The SEM was 
operated with 25 kV and examined areas on grafts were chosen so that 2100 counts 
per second (CPS) were registered and dead time was 30–35%. Measurements were 
performed for a period of 200 live seconds (Lsec). Three donors were used for each 
bone graft material. Each cylinder was measured twice at two different surface areas 
of the graft. 
 
2.3 Comparison of reseeding properties with MSCs  
 
2.3.1 Isolation and culture of MSCs 
MSCs were isolated from cancellous bone of the femoral heads obtained from patients 
undergoing total hip replacement surgery. Isolation was performed as previously 
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mentioned [114,115]. Femoral heads were received from patients undergoing total hip 
replacement surgery.  Upon receival, femoral heads had been pre-cut in the operating 
room into quarters and were placed in tissue buffer preheated to 37°C. Working with 
sterile surgical gloves, pieces of cancellous bone were collected from the bone with a 
Luer forceps (Aesculap, Tuttlingen, Germany). Cancellous bone fragments were 
collected in Falcon 50mL tubes and PBS was added. After thoroughly shaking the tube, 
PBS was transferred to a new tube and the process was repeated until approximately 
6-8 Falcon tubes with PBS washing solution were obtained. Tubes with PBS wash 
solution were then centrifuged at 400 x g for 10 min. After the supernatant was 
aspirated the cell pallet on the bottom of the tube was reconstituted with 5 mL buffy 
coat buffer, consisting of PBS, 0.5% (v/v) FBS and 2 mM Ethylendiaminetetraacetat 
(EDTA) (SERVA, Heidelberg, Germany). Resuspended cells were then collected and 
run through a 40 µm cell strainer (Falcon, Durham, USA) and counted using an 
automated cell counter (CASY TT, OLS, Bremen, Germany). Cells were seeded in 
T175 flasks coated with collagen type I (Corning, Bedford, MA, USA) at a density of 
2x106 cells/cm2 and incubated at 37°C in Dulbecco’s Medium Essential Medium 
(DMEM)/Ham’s F-12 medium (Biochrom, Berlin, Germany) supplemented with 20% 
(v/v) FBS and 1% (v/v) Pen/Strep for the first 14 days. The first medium change was 
performed 24 hours after seeding to remove cells that had not attached to the flask. 
Henceforth, the medium was changed three times a week. After splitting cells from 
passage 0 to passage 1, culturing was continued using 10% (v/v) FBS. In passage 2 
osteogenic differentiation of MSCs was induced by incubation in osteogenic 
differentiation medium (ODM) for a minimum of two weeks consisting of DMEM/Ham’s 
F-12, 10% (v/v) FBS, 1% (v/v) Pen/Strep, 10 mM β-glycerophosphate (Sigma-Aldrich, 
Darmstadt, Germany), 0.1 μM dexamethasone (Sigma-Aldrich, Darmstadt, Germany) 
and 50 μM ascorbic acid (Sigma-Aldrich, Darmstadt, Germany). Experiments with 
MSCs were conducted with cells in passage no. 4 and 5. 
 
2.3.2 Biocompatibility testing using extracts obtained from decellularized 
bone grafts 
In order to assess the biocompatibility of decellularized grafts, extracts of CPAs, SPAs, 
TPAs and BPXs were prepared according to ISO 10993. Then, the effect of extracts 
on MSC viability was assessed using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). Extracts were created by 
incubating decellularized bone grafts in 750 μL ODM at 37°C for either 24 hours or 72 
hours and stored at -20°C until use. MSCs were seeded at a density of 45,500 
cells/cm2 in a 96 well-plate (Sarstedt, Nümbrecht, Germany) that had been pre-coated 
with 33.6 μg/mL collagen type I solution diluted in PBS. After allowing cells to attach 
for 24 hours, ODM was aspirated, extracts were defrosted, centrifuged at 12,000 x g 
for 5 min, added to the cells and incubated for 48 hours. Metabolic activity of MSCs 
was assessed using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI, USA) according to manufacturer’s instructions. The MTS 
compound is a reagent that can be bioreduced by cells into a colored product and is 
presumed to be accomplished by dehydrogenase enzymes in metabolically active 
cells. Thus, the metabolic activity can be quantified colorimetrically. After incubating 
the cells with the extracts for 48 hours the extract solution was aspirated, and 100 µL 
of MTS reagent solution and 20 µL of ODM was added to the wells. After 2 hours of 
incubation the optical density was measured with a microplate reader (TECAN, 
Maennedorf, Switzerland) at 490 nm. Three MSC donors and three distinct bone 
donors for CPAs and SPAs were used to assess biocompatibility in technical 
triplicates. Data were depicted in relation to untreated controls. 
 
2.3.3 Seeding of MSCs onto constructs 
After coating grafts with 10 μg/mL fibronectin (Millipore, Temecula, CA, USA) 200,000 
MSCs were drop seeded in a volume of 100 μL ODM onto precoated CPAs, SPAs, 
TPAs and BPXs, placed in 48-well plate wells. After cells were left to attach to grafts 
for 1 hour at 37°C 650 μL of ODM was added and medium was exchanged three times 
a week. 
 
2.3.4 Evaluation of MSC-seeded constructs by CLSM and SEM 
microscopy 
After 7 days of cultivation, MSC-seeded constructs were fixed in 4% PFA solution 
followed by three wash cycles in PBS for 15 min and twice for 5 min. Samples were 
then treated with 0.5% (v/v) Triton X-100 diluted in PBS for 20 min. This was followed 
by washing in PBS. Intracellular F-actin was stained with 5 μg/mL 
tetramethylrhodamine (TRITC)-conjugated phalloidin (Sigma-Aldrich, Darmstadt, 
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Germany) in 1% (v/v) bovine serum albumin (BSA) (Millipore, Kankakee, USA) in PBS 
for 30 min. Hoechst 33258 (Sigma-Aldrich, Darmstadt, Germany) at a concentration of 
2 μg/mL in PBS for 15 min was used for nuclear counterstain. Samples were imaged 
by confocal laser scanning microscope (CLSM) (LSM 510 Meta, Zeiss, Oberkochen, 
Germany). After CLSM, MSC-seeded constructs were prepared for SEM as described 
above. 
 
2.3.5 DNA quantification of MSC-seeded constructs 
In order to evaluate cell attachment and cell proliferation of MSCs on SPAs, TPAs and 
BPXs, DNA quantification was performed on day 1, day 7 and day 14 after cell seeding. 
MSC-seeded constructs were transferred into new 48 well-plate wells and DNA was 
extracted by performing three freeze/thaw cycles at -80°C after the addition of 
nuclease-free water, followed by sonication at a frequency of 20 kHz and an amplitude 
of 12 microns for 30 seconds. At each time point DNA quantification was performed 
for two independent grafts and technical replicates for 3 donors. DNA quantification 
was performed as described above. 
 
2.3.6 ALP assay 
ALP activity was measured from supernatants of MSC-seeded constructs after day 
one, day seven and day fourteen using an alkaline phosphatase assay kit (Abcam, 
Cambridge, UK). Measurements were run in technical triplicates and ALP activity 
measurements were performed according to manufacturer’s instructions. Based on 
this kit, an ALP enzyme solution serves as a standard from which a standard curve is 
calculated. P-nitrophenyl phosphate (pNPP) is used as a substrate that can be 
dephosphorylated by ALP to p-Nitrophenol (pNP) and measured photocolorimetrically 
at OD 405 nm as a result of its change in color. ALP activity (in U/mL) was calculated 
as follows: # !
∆#	%	&
$ ∗ 𝐷, where B equals the amount of pNP in sample well calculated 
from the standard curve (µmol), ΔT equals the reaction time (in minutes), V equals the 
original sample volume added into the reaction well (mL) and D equals the dilution 
factor. Measurements were normalized to 1 μg DNA at the indicated time points. At 
each time point, ALP quantification was performed for two independent grafts and 
technical replicates for 3 donors. 
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2.3.7 Alizarin Red S quantification 
Alizarin Red S staining was performed to assess mineralization of MSCs on SPAs, 
TPAs and BPXs. After 7 and 14 days of cultivation, MSC-seeded constructs were fixed 
in 4% PFA for 1 hour in a 48-well plate, washed three times with PBS and consecutively 
incubated in 500 μL Alizarin Red S staining solution (40 mM, Merck, Darmstadt, 
Germany) for 60 min at room temperature on an orbital shaker. After washing MSC-
seeded constructs with distilled water in order to remove any excess, Alizarin Red S 
was extracted using a 10% (w/v) cetylpyridinium chloride (CPC) solution (Carl Roth, 
Karlsruhe, Germany) for 48 hours in a new 48-well plate. Finally, extracted Alizarin 
Red S was quantified by measuring the optical density at 560 nm and calculated in 
accordance with the standard curve. At each time point, Alizarin Red S quantification 
was performed for two independent grafts and technical replicates for 3 donors. 
 
2.4 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 7. Statistical significance 
was assessed using ANOVA, as indicated in the individual experiments. A p-value 
of p < 0.05 (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) was considered to 




3.1 Comparison of two decellularization approaches 
 
3.1.1 Histological examination of decellularized allografts 
Histological examination of decellularized bone grafts with toluidine blue staining was 
performed in order to assess the decellularization efficacy of chemical and sonication-
based decellularization protocols (Figure 4). Untreated controls (Figure 4A) show 
trabecular structures in blue and marrow cavities extensively filled with bone marrow. 
Higher magnification of this sample (Figure 4B) shows deposited matrix peripherally to 
the trabecular structures (white arrow). Furthermore, cells showing the morphology of 
adipocytes can be detected in the marrow cavity (thin black arrow). CPAs only contain 
little to no marrow content (Figure 4C). However, some trabecular fragments in the 
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marrow cavities (thick black arrow) can be seen (Figure 4D). SPAs show completely 
empty marrow cavities and very distinct trabecular structures (Figure 4E). Higher 
magnification (Figure 4F) confirms marrow cavities void of any material.  
Figure 4. Histological assessment of chemically processed allografts, sonication-based 
processed allografts and controls. Toluidine blue stained sections show untreated control 
allografts (A, B), chemically processed allografts (C, D) and sonication-based processed 
allografts (E, F). Images document less cells and residues of bone marrow in sonication-based 
processed allografts compared to chemically processed allografts and control. White arrow (B) 
points to deposited matrix, thin black arrow (B) to peripherally located nuclei of adipocytes 
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and black thick arrows (D) point to trabecular fragments. Images A, C, E show stitched images 
using 42 individual images. Scale bar: A, C, E = 1 mm, B, D, F = 150 µm. 
 
3.1.2 SEM images of decellularized allografts 
In order to confirm histological examination and to further assess the surface 
topography of decellularized bone grafts, SEM images were taken (Figure 5). SEM 
images of untreated controls (Figure 5A) display a similar surface structure compared 
to CPAs (Figure 5C). Surface structure of SPAs (Figure 5E) differs visually from 
controls and CPAs. Additionally, SPAs (Figure 5F) display more trabecular structures 
devoid of bone marrow or soft tissue in the cavities compared to CPAs (Figure 5D). 
CPAs show a surface topography that resembles those of untreated control grafts 
(Figure 5B).  
Figure 5. Scanning electron microscope assessment of chemically processed allografts, 
sonication-based processed allografts and controls. Scanning electron microscope images 
show untreated control allografts (A, B), chemically processed allografts (C, D) and sonication-
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based processed allografts (E, F). Scanning electron microscope images depict more empty 
marrow cavities for sonication-based processed allografts in comparison to chemically 
processed allografts and control. Scale bar: A, C, E = 50 µm, B, D, F = 500 µm.  
 
3.1.3 DNA quantification of decellularized allografts 
In order to further verify and assess the efficacy of the decellularization protocols for 
CPAs and SPAs, DNA was quantified. Furthermore, as additional references and 
controls, DNA contents of commercially available and standardized grafts (TPAs and 
BPXs) were measured (Figure 6). DNA is depicted as absolute values (Figure 6A) and 
in relation to control allografts that had not been decellularized (Figure 6B). 
Decellularized CPAs revealed a mean value of 15,304 ng DNA. SPAs yielded a mean 
value of 40.3 ng, while controls showed an average of 58,279 ng. TPAs and BPXs 
yielded a total amount of 7.4 ng and 0.49 ng DNA, respectively. In relation to untreated 
controls, CPAs showed a non-significant DNA reduction to 85.98%, while SPAs 
showed a significant DNA reduction to 0.11%. Compared to controls, DNA levels of 
TPAs and BPXs showed a significant DNA reduction to 0.01% and 0%, respectively. 
These data suggest a much more effective decellularization for the SPA compared to 
CPA processed grafts. Decellularization efficacy for SPA was tentatively lower but still 














Figure 6. DNA quantification of chemically processed allografts, sonication-based processed 
allografts, and commercially available allografts (Tutoplast processed allografts) and 
xenografts (Bio-Oss processed xenografts). Highest amounts of residual DNA were detected in 
chemically processed allografts which differed significantly from SPAs, based on Tukey’s 
multiple comparison in conjunction with ANOVA. TPAs and BPXs show low amounts of DNA 
(A). Values of sonication-based processed allografts, TPAs and BPXs are significantly lower 
compared to control (B), as assessed by Tukey’s multiple comparison in conjunction with 











3.1.4 EDX analysis 
Element analysis was performed by EDX spectroscopy to reveal the elemental 
composition of CPAs and SPAs and compare it to commercially available TPAs and 
BPXs. Figure 7A shows significant differences in atomic percentage (At%) between 
CPAs and SPAs for oxygen (O) (12.88%) and nitrogen (N) (-10.06%). Among all bone 
grafts, TPAs displayed the least amount of calcium (Ca) and phosphorous (P) and the 
highest amount of N, differing significantly from all other tested grafts. BPXs showed 
the highest values in Ca and P, including significant differences to CPAs and TPAs 
with regard to Ca and significant differences to TPAs with regard to P. Values for N in 
BPXs were low, showing significant differences to SPAs and TPAs. Since it has 
previously been shown that grafts with a Ca/P ratio of ∼ 1.43 can induce osteogenesis 
[106], Ca/P ratios were displayed (Figure 7B). In addition, Ca/N and O/Ca ratios were 
displayed as N and O are ubiquitous in many organic compounds. For the bone 
essential Ca/P ratios did not differ significantly between grafts. However, TPAs showed 
the lowest Ca/N ratio whereas the O/Ca ratio was highest, showing significant 
differences compared to all other grafts.  
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Figure 7. Energy-dispersive x-ray spectroscopy analysis of chemically processed allografts, 
sonication-based processed allografts, Tutoplast processed allografts and Bio-Oss processed 
xenografts. Analysis shows element composition in atomic percentage (At%) (A) and Ca/P, 
Ca/N and O/Ca ratios (B) in order to assess chemical composition. Tutoplast processed 
allografts show the highest amount of N, a low Ca/N ratio and high O/Ca ratio while Bio-Oss 
processed xenografts show the highest values for Ca and P. Statistics are based on Tukey’s 
multiple comparison in conjunction with ANOVA (n = 3 donors, two different surface areas 






3.2 Comparison of reseeding properties with MSCs 
 
3.2.1 Biocompatibility testing using extracts obtained from decellularized 
bone grafts 
In order to assess potentially harmful substances leaking out of the processed bone 
grafts, extracts were created by adding ODM to CPAs, SPAs, TPAs and BPXs and 
biocompatibility was assessed by MTS assay using MSCs. Extracts were created by 
incubating allografts and xenografts in ODM for 24 hours and 72 hours and were then 
added to MSCs on 96 well-plates 24 hours after seeding. After 48 hours of exposure 
to extracts, MTS assay was performed. Images of seeded MSCs were taken 24h hours 
after treatment using EVOS microscope in translucent mode.  
 
3.2.1.1 Testing of grafts with in-between freezing  
SPAs and CPAs used for biocompatibility testing were processed and decellularized 
as described above. Initially, SPAs and CPAs were frozen in -80°C after 
decellularization for practical reasons. Results of MTS assay (Figure 8A) performed 
after 48 hours of exposure to the extracts (extraction time 24 hours) showed an 
average of 1.84% of cell viability for CPAs, while cell viability for SPAs was 15.93%. 
BPXs, which were commercially acquired and had not been frozen, showed an 
average amount of 47.61%. Corresponding microscope images (Figure 8B), taken 48 
hours after exposure to extracts of CPAs, SPAs and BPXs, depict low cell densities for 
all grafts, while cells treated with extracts from BPXs show the largest cell size and 
CPAs the smallest cell size. Additionally, cells treated with extracts from CPAs 





Figure 8. Biocompatibility testing with mesenchymal stem cells performed for extracts of 
chemically processed allografts and sonication-based processed allografts in-between frozen 
and Bio-Oss processed xenografts. Allografts and xenografts, which had been stored at -80°C 
in-between, were incubated in osteogenic differentiation medium for 24 hours to create 
extracts. Extracts were then added to mesenchymal stem cells on 96 well-plates after cell 
attached to wells for 24 hours. After 48 hours of exposure to extracts MTS assay was performed 
(A). Chemically processed and sonication-based processed allografts show poor levels of cell 
viability after treatment with extracts. Cell viability of chemically processed allografts differed 
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significantly from control. Corresponding images taken 48 hours after exposure to extracts 
show a similar pattern (B). Statistics are based on Tukey’s multiple comparison in conjunction 
with ANOVA (n = 2 donors, measurements were performed in technical triplicates, * p < 0.05). 
 
3.2.1.2 Testing of grafts with in-between freezing and centrifugation of extracts 
Since initial biocompatibility testing, described above, showed poor results for CPAs 
and SPAs, a proposal was made to see whether centrifuging extracts prior to usage 
would increase the cell viability. As such, extracts of CPAs, SPAs and also BPXs were 
centrifuged at 12,000 x g for 5 min prior to incubation with MSCs. However, as seen in 
Figure 8, cell viability for CPAs and SPAs still stayed below 2% for 24-hour extracts 
(Figure 9A) and 72-hour extracts (Figure 9B). Cell viability of BPXs stayed at 44.45%. 
Cells in corresponding images (Figure 9C) taken 48 hours after exposure to extracts 
appear to show a similar morphology and cell density as images in previous figure 






















Figure 9. Biocompatibility testing with mesenchymal stem cells performed for extracts of 
chemically processed allografts and sonication-based processed allografts in-between frozen 
and centrifuged and Bio-Oss processed xenografts centrifuged. Allografts and xenografts, 
which had been stored at -80°C in-between, were incubated in osteogenic differentiation 
medium for 24 hours (A) or 72 hours (B) to create extracts. After centrifugation at 12,000 x g 
for 5 min extracts were added to mesenchymal stem cells on 96 well-plates after cell attached 
to wells for 24 hours. After 48 hours of exposure to extracts, MTS assay was performed. 
Chemically processed allografts and sonication-based processed allografts show poor levels of 
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cell viability after treatment with extracts. Cell viability of chemically processed allografts 
differed significantly from control. Corresponding images taken 48 hours after exposure to 
extracts show a similar pattern (C). Statistics are based on Tukey’s multiple comparison in 
conjunction with ANOVA (n = 3 donors, measurements were performed in technical 
triplicates, * p < 0.05, **** p < 0.0001). 
 
3.2.1.3. Testing of grafts with in-between freezing and sterile filtering of extracts 
As the causing agent for the reduction in cell viability could not be removed using 
centrifugation, a proposal was made to sterile filter the extracts prior to the addition of 
MSCs. This was accomplished by using a 0.2 µm filter (Sarstedt, Nümbrecht, 
Germany) through which the extracts were passed prior to incubation with MSCs. 
Figure 10 displays microscopy images of cells 48 hours after treatment. MSCs treated 
with ODM as control showed a high cell density with an elongated cell morphology. 
Cells treated with extracts from CPAs showed a low cell density with a mostly roundish 
morphology. Cell morphology in images of cells treated with extracts obtained from 




















Figure 10. Biocompatibility testing with mesenchymal stem cells performed for extracts of 
chemically processed allografts and sonication-based processed allografts in-between frozen 
and sterile filtered. Allografts which had been stored at -80°C in-between, were incubated in 
osteogenic differentiation medium for 24 hours to create extracts. After sterile filtration with 
a 0.2 µm filter, extracts were added to mesenchymal stem cells on 96 well-plates after cell 
attached to wells for 24 hours. After 48 hours of exposure to extracts, microscopy images were 
recorded. Mesenchymal stem cells treated with osteogenic differentiation medium as control 
showed a high cell density with an elongated cell morphology. In contrast to the control, cells 
treated with extracts from chemically processed allografts and sonication-based processed 









3.2.1.4 Testing of grafts without in-between freezing and centrifugation of extracts 
Up to this point, neither centrifuging extracts at 12 000 x g for 5 min nor sterile filtering 
them before adding them to MSCs showed any significant improvement of MSC 
viability.  
Initially, CPAs and SPAs were stored at -80°C as decellularization according to the 
decellularization protocols for CPAs and SPAs as described above was completed. 
This was done so that experiments could be started for both grafts at the same time 
as the decellularization process endured different time lengths and to preserve the 
grafts in their decellularized status. As none of the above-mentioned methods resolved 
the issue of low biocompatibility of the extracts based on MSC cell viability, the 
proposal was made that the in-between freezing of the allografts for storage until usage 
could potentially liberate apoptosis inducing agents. Thus, CPAs and SPAs were not 
frozen at -80°C after decellularization for storage but were rather store at 4°C until 
usage and extract were additionally centrifuged at 12,000 x g for 5 min. Results of MTS 
assay using 24-hour extracts showed a cell viability for CPA extracts of 62.04%, for 
SPA extracts 51.17% and BPX extracts 36.94% (Figure 11A). TPA extracts were 
additionally added to biocompatibility testing and in contrast to all other grafts showed 
a non-significant increase (112.28%). Extracts gained by 72-hour extraction time 
showed similar results (Figure 11B). Accordingly, the highest values in cell viability 
were observed for TPAs. In conjunction with the increased cell viability in CPAs and 
SPAs microscopy images (Figure 11C) taken after treatment with extracts showed a 
change in morphology in comparison to previous trials from a roundish, dysmorphic to 
an elongated spindle-like cell morphology. However, compared to controls, cell density 











Figure 11. Biocompatibility testing with mesenchymal stem cells performed for extracts of 
chemically processed allografts and sonication-based processed allografts not in-between 
frozen and Tutoplast processed allografts and Bio-Oss processed xenografts. Allografts and 
xenografts, which had been stored at 4°C in-between, were incubated in osteogenic 
differentiation medium for 24 hours (A) or 72 hours (B) to create extracts. After centrifugation 
at 12,000 x g for 5 min extracts were added to mesenchymal stem cells on 96 well-plates after 
cell attached to wells for 24 hours. After 48 hours of exposure to extracts MTS assay was 
performed. Chemically processed allografts and sonication-based processed allografts now 
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show levels of cell viability similar to Bio-Oss processed xenografts (A and B). In comparison 
to all other grafts, Tutoplast processed allografts showed no reduction in cell viability. 
Corresponding images taken 48 hours after exposure to extracts now show an elongated, 
spindle-like morphology of mesenchymal stem cells treated with extracts from chemically 
processed allografts and sonication-based processed allografts (C). Statistics are based on 
Tukey’s multiple comparison in conjunction with ANOVA (n = 3 donors, measurements were 
performed in technical triplicates, * p < 0.05, ** p < 0.01). 
 
Comparing the treatment groups with 24-hour extracts (Figure 12) previously 
described, a significant increase in cell viability could be observed between extracts of 
CPAs and SPAs which had been created after grafts were stored at -80°C after 
decellularization vs. grafts that were stored at 4°C. Extract that had been created from 
grafts stored at -80°C and had additionally been centrifuged prior to addition to cells 
did not show any increase in cell viability. Extracts obtained from BPXs did not show 
any significant increase in cell viability when extracts were centrifuged.  
As extracts obtained from CPAs and SPAs by storing at 4°C showed a significant 
increase in cell viability in-between storage at -80°C was abandoned and for all 
experiments in conjunction with MSCs grafts were henceforth stored at 4°C until use.  
Figure 12. Biocompatibility testing performed with mesenchymal stem cells for 24-hour 
extracts of chemically processed allografts, sonication-based processed allografts and Bio-Oss 
processed xenografts using different protocols. Displayed are 3 different treatment groups of 
grafts. First, chemically processed allografts and sonication-based processed allografts were 
stored at -80°C after decellularization. Extracts were added directly to mesenchymal stem 
cells. Second, all extracts were centrifuged at 12,000 x g for 5 min prior to addition to 
mesenchymal stem cells. Third, chemically processed allografts and sonication-based 
processed allografts were not stored at -80°C but were kept at 4°C until use. These extracts 
were also centrifuged.  
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MTS assay was performed after cells were incubated with extracts for 48 hours. Statistics are 
based on Tukey’s multiple comparison in conjunction with ANOVA (n = 2 donors black bars, 
n = 3 donors grey bars, measurements were performed in technical triplicates, *** p < 0.001, 
**** p < 0.0001). 
 
3.2.2 Evaluation of MSC-seeded constructs by CLSM and SEM 
microscopy 
While previous results characterized SPAs and CPAs after the decellularization, the 
following results were obtained after these grafts were reseeded with MSCs. First, 
CLSM images of cell- seeded constructs were taken 7 days after seeding (Figure 13). 
F-Actin staining was used to visualize the cytoskeleton and cells were depicted in 
combination with nuclear counterstain. Images of cell-seeded CPAs (Figure 13A and 
13B) display some background fluorescence in the red channel due to the material 
properties interfering to some extent with a distinct fluorescence pattern for the 
cytoskeleton. Nevertheless, several nuclei are visible, confirming the presence of cells 
on CPAs. Images of cell-seeded SPAs (Figure 13C) show abundant numbers of MSCs 
revealing an elongated morphology with centrally located nuclei (Figure 13D). CLSM 
images of cell-seeded TPAs (Figure 13E) show a high cell density. Upon higher 
magnification (Figure 13F), cells seem to display a smaller morphology than cells on 
SPAs (Figure 13D). MSCs on BPXs (Figure 13G and 13H) show cellular protrusions 
with a morphology not as elongated compared to SPAs and TPAs. Additionally, the 
cell density appears to be lower than on MSC-seeded SPAs and TPAs.  
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Figure 13. Morphology assessment of seeded mesenchymal stem cells on chemically processed 
allografts, sonication-based processed allografts, Tutoplast processed allografts and Bio-Oss 
processed xenografts using confocal laser scanning microscopy. Images display mesenchymal 
7 days after seeding onto chemically processed allografts (A, B), sonication-based processed 
allografts (C, D), Tutoplast processed allografts (E, F) and Bio-Oss processed xenografts (G, H) 
stained with TRITC-conjugated phalloidin / Hoechst nuclear stain co-stain. Images of 
chemically processed allografts depict cells, but as well, high levels of background fluorescence. 
mesenchymal stem cells on Bio-Oss processed xenografts show a lower cell density than cells 
on sonication-based processed allografts and Tutoplast processed allografts. Scale bars: A, C, 
E, G = 100 µm, B, D, F, H = 50 µm.  
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SEM images of MSC-seeded constructs shown in Figure 14 reflect findings from CLSM 
images. Cell-seeded CPAs (Figure 14A and 14B) display elongated cells and nuclear 
protrusions (white arrows). MSC-seeded SPAs also show elongated cells with several 
nuclear protrusions (Figure 14C and 14D). Congruent to CLSM images, MSCs on 
TPAs (Figure 14E) display a smaller morphology with a high number of cellular 
processes (Figure 14F). Seeded BPXs (Figure 14G and 14H) show few cells with few 
elongated processes analogous to Figure 13H.  
Figure 14. Morphology assessment of seeded mesenchymal stem cells on chemically processed 
allografts, sonication-based processed allografts, Tutoplast processed allografts and Bio-Oss 
processed xenografts using scanning electron microscopy. Images show mesenchymal stem 
cells 7 days after seeding onto chemically processed allografts, (A, B), sonication-based 
processed allografts (C, D), Tutoplast processed allografts (E, F) and Bio-Oss processed 
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xenografts (G, H). Chemically processed allografts, sonication-based processed allografts and 
Tutoplast processed allografts show elongated spindle-like cells while mesenchymal stem cells 
on Bio-Oss processed xenografts appear to be fewer in number. White arrows point to nuclear 
protrusions. Scale bars: A, C, E, G = 100 µm, B, D, F, H = 50 µm.  
 
3.2.3 DNA quantification of MSC-seeded constructs  
Cell adhesion to grafts (day 1) as well as the rate of proliferation (day 7 and 14) of 
MSCs on SPAs, TPAs and BPXs was determined by DNA quantification (Figure 15). 
The DNA content of corresponding unseeded grafts was subtracted as background for 
each group. In consequence to the results from Figure 6 where CPAs did not reveal a 
sufficient level of decellularization, CPA data were excluded from quantitative 
evaluation of the MSC performance after reseeding.  
DNA quantification after reseeding showed a significant increase of MSC numbers 
grown on TPAs on day 14 (2077 ng) compared to day 1 (685.7 ng) and day 7 (864.5 
ng), thus indicating the proliferation of MSCs on TPAs in the investigated time frame. 
In addition, after 14 days, significant differences in DNA amounts were observed for 
TPAs and SPAs, suggesting a better performance of MSCs on TPAs after reseeding. 
Although the cell growth on BPXs also showed a tentative increase up to 14 days 
(796.5 ng), DNA quantification data did not reveal significant differences for the 
investigated time points. Similar amounts of DNA were observed on day 1 for TPAs, 
SPAs and BPXs suggesting that the initial adhesion is comparable.  
Figure 15. DNA quantification of mesenchymal stem cells 1, 7 and 14 days after seeding onto 
sonication-based processed allografts, Tutoplast processed allografts and Bio-Oss processed 
xenografts. Tutoplast processed allografts show a significant increase in DNA from day 1 and 
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day 7 to day 14, suggesting proliferation of mesenchymal stem cells. Furthermore, DNA levels 
differed significantly between sonication-based processed allografts and Tutoplast processed 
allografts on day 14 indicating better cell growth on Tutoplast processed allografts. DNA 
background values determined for empty grafts (compare Figure 5) were subtracted from 
values obtained after mesenchymal stem cell-seeding. Statistics are based on Tukey’s multiple 
comparison in conjunction with ANOVA (n = 3 mesenchymal stem cell donors and 3 graft 
donors, two independent mesenchymal stem cell-seeded constructs were quantified per donor, 
* p < 0.05, ** p < 0.01, *** p < 0.001).  
 
3.2.4 Osteogenic activity determined by ALP assay  
Furthermore, ALP activity as an early marker for osteogenic differentiation was 
measured in order to assess MSC functionality on the grafts (Figure 16A). For this 
purpose, medium retrieved from MSC-seeded constructs was collected on day 1, 7 
and day 14 and ALP levels were normalized to the corresponding DNA content 
(compare Figure 15) in order to cope with a potential impact of the cell numbers on the 
ALP activity. BPXs displayed a tentative, yet non-significant increase of normalized 
ALP activity from day 1 to day 7. ALP levels of SPAs showed no significant increase 
or decrease throughout the 14-day period while TPAs showed a significant decrease 
from day 1 to day 14 in the alkaline phosphatase activity as early osteogenic marker.  
 
3.2.5 Quantification of mineralization of cell seeded constructs by Alizarin 
Red S  
Mineralization of MSC-seeded grafts was assessed by Alizarin Red S (Figure 16B) and 
included the subtraction of background values derived from grafts before cell seeding 
(see Supplemental Figure 1). Additionally, Alizarin Red S levels were normalized to 
the corresponding DNA content (Figure 16B, upper graph) to cope with a potential 
impact of the cell numbers on the degree of mineralization (compare Fig 15). After 
normalization to the DNA content, BPXs displayed a tentative yet non-significant 
increase in mineralization from 26.6 mM/μg DNA on day 7 to 69.3 mM/μg DNA on day 
14. However, increased mineralization levels for both BPXs and TPAs were 
documented when alizarin quantification was not normalized to DNA content (Figure 
15B, lower graph).  
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Figure 16. Alkaline phosphatase quantification (A) of cell-seeded constructs 1, 7 and 14 days 
and Alizarin Red S quantification (B) 7 and 14 days after seeding mesenchymal stem cells onto 
sonication-based processed allografts, Tutoplast processed allografts and Bio-Oss processed 
xenografts. (A) Alkaline phosphatase quantification was performed from supernatant retrieved 
from seeded grafts on day 1, 7 and 14. Alkaline phosphatase levels were normalized to DNA 
amount (compare Figure 14). Bio-Oss processed xenografts show the highest tentative, yet 
non-significant increase in Alkaline phosphatase levels from day 1 to day 7. Tutoplast 
processed allografts show a significant decrease from day 1 to day 14. (B) Alizarin Red S values 
were also normalized to corresponding DNA levels (Figure 15B, upper graph). Normalized data 
indicate the most prominent yet non-significant increase in calcification for Bio-Oss processed 
xenografts. Alizarin Red S data not normalized to DNA however (Figure 15B, lower graph) 
indicate a significant increase in calcification for both Bio-Oss processed xenografts and 
Tutoplast processed allografts. Statistics are based on Tukey’s multiple comparison in 
conjunction with ANOVA (n = 3 mesenchymal stem cell donors and 3 graft donors, two 
independent mesenchymal stem cell-seeded constructs were quantified per donor, * p < 0.05, 




4.1 Assessment of degree of decellularization 
The increased incidence of bone defects, especially in cases of comminuted fractures 
or non-unions demand suitable bone grafts and therefore rising amounts of suitable 
allografts are required. Currently, several decellularization methods for allografts have 
been proposed but it still remains unclear which method results in favorable 
physiochemical properties or might be preferred in stem cell applications. Hence, the 
aim of this study was firstly to compare two decellularization methods concerning their 
decellularization capacity for bone grafts, and secondly, to investigate their impact on 
MSC functionality together with two commercially available grafts. 
 
4.1.1 Comparing decellularization of chemically processed allografts to 
sonication-based processed allografts 
Based on histological examination, SEM examination and DNA quantification, a higher 
efficacy in decellularization could be shown for SPAs in comparison to CPAs. This was 
documented by significantly higher amounts of DNA after decellularization in CPAs 
compared to SPAs, although CPAs were treated with DNase in an additional step. 
Similarly, SEM images revealed marrow cavities filled with tissue, underscoring 
incomplete decellularization in CPAs. SPAs, on the other hand, showed empty marrow 
cavities, revealing a rough surface structure and distinct trabecular structures. The 
increased clearance of marrow cavities in SPAs over CPAs might be due to the 
disrupting effect of sonication on cell membranes [116]. Additionally, mechanical 
energy exerted by sonication possibly helped to clear any residues [117]. In this study 
we treated SPAs, as mentioned above, by sonicating grafts at 20 kHz with an amplitude 
of 12 microns. This is in accordance to previous reports showing this frequency to have 
a cell membrane disrupting effect and a significant reduction in cell viability [116,118]. 
It is important to note that the efficacy of decellularization for SPAs in our experiments 
was comparable to TPAs and BPXs as commercial standardized products. 
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4.1.2 Decellularization of Tutoplast® processed allografts and Bio-Oss® 
processed xenografts 
Commercially available TPAs are generated by a combination of chemical and physical 
treatment steps including sonication, acetone treatment, osmotic treatment, 
sterilization via hydrogen peroxide solutions, serial dehydration and gamma irradiation 
[109,119]. BPXs differ from all other grafts as they originate from a bovine source and 
are treated with heat (300°C), alkaline chemicals and sterilization using dry heart [119]. 
This process is supposed to remove any proteins or antigenic structures [120]. 
Nevertheless, assessment of protein content, or the presence of immune response 
mediating material was not in the scope of this present study. 
 
4.2 Biocompatibility issues 
Initial biocompatibility testing based on extraction medium from grafts showed 
unsatisfactory levels of cell viability at ∼	1% to ∼	16% in CPAs and SPAs (Figure 8). 
BPXs, as reference for a commercially available graft, showed levels at ∼	50% while 
untreated medium was used as negative control (100%). Though the decrease of cell 
viability might be due to a variety of different agents acting in a biological, chemical or 
physical manner, the proposal was made to centrifuge extracts at 12,000 x g for 5 min 
in an effort to increase cell viability. Differential centrifugation at ∼	10,000 x g is known 
to form a pellet with mitochondria and subcellular particles [121], as well as particles 
with a larger size, such as cells [122] or bone debris [123] which already separate at 
lower speeds. However, centrifuging the extracts before addition to MSCs did not show 
an increase in cell viability (compare Figure 9 and Figure 12). In an attempt to remove 
any cell viability reducing agent which could induce apoptosis, extracts were sterile 
filtered with a pore size of 0.2 µm. Seeing as how this approach did not increase cell 
viability either (see Figure 10), a change of protocol concerning the storage of the grafts 
after decellularization was performed. Initially, before CPAs and SPAs were used in 
experiments, they were stored at -80°C for practical reasons. It was proposed, that this 
re-freezing could have an effect on the integrity of the graft and lead to the liberation 
of harmful substances. Thus, in-between storage was kept to a minimum and 
performed at 4°C. This change in protocol significantly raised the cell viability of both 
CPAs and SPAs to ∼	50% to ∼	60% (see Figure 11 and Figure 12), being comparable 
to cell viability values of BPXs. Even though BPXs were never frozen, as they were 
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acquired commercially and stored at room temperature, extracts derived from BPXs 
did not show a significant increase in cell viability when extracts were treated as 
mentioned above.  
The only graft showing no reduction in cell viability compared to controls were TPAs 
(Figure 11). Results for TPAs are congruent with other published data showing 
favorable cell viability properties for TPAs [107,124].  
Even though changing the protocol from storage at -80°C to storage at 4°C significantly 
increased the cell viability in CPAs and SPAs to ∼	50% to ∼	60%, cell viability levels 
still differed significantly from controls. This reduction of cell viability in CPAs, SPAs 
and also BPXs might be due to a variety of different reasons and its underlying 
biological mechanisms.  
 
4.2.1 Biocompatibility of chemically processed allografts and sonication-
based processed allografts  
The reduction in MSC viability for CPA extracts might be caused by chemical 
substances such as Triton X-100 and SDS, used in the decellularization process 
leaking out even after thorough washing. On the other hand many potential mediators 
such as TNF-α [125], cytochrome c [126] and miRNA released by cells during the 
decellularization method, or in not completely decellularized materials, might lead to 
reduced cell viability in MSCs treated with the extracts. Although the procedure 
includes intensive washing, an impact of such molecules cannot be excluded but might 
be determined in future studies.  
 
4.2.2 Biocompatibility of Bio-Oss® processed xenografts 
BPX extracts also induced a reduction in MSC cell viability. As BPXs have been shown 
to be void of any cellular material (Figure 4), and as a result, the above-mentioned 
explanations are not applicable to this graft. Though our findings are in line with other 
published data showing a reduction in cell viability [127,128], to our knowledge, no 
explanation has yet been given. Considering that BPXs mainly consist of 
hydroxyapatite and have a very porous consistency, a tentative explanation could 
constitute the induction of apoptosis by nanoparticles [129]. Even though our results 
regarding BPXs are consistent with in vitro data, it should be noted that a discrepancy 
between results from experiments in vitro and in vivo cannot be excluded. While in 
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vitro testing often offers the ability to study cellular and molecular processes more 
closely, a direct translation to an in vivo setting might often be limited. In fact, BPXs 
have repeatedly been shown to integrate well in vivo by demonstrating large quantities 
of osteoid matrix depositions and being enveloped well by adjacent tissue [130,131]. 
 
4.3 Mesenchymal stem cell functionality 
The impact of graft processing on the graft’s ability to host MSCs was assessed by 
examining cell morphology and cell density of seeded MSCs.  
 
4.3.1 MSC morphology and proliferation rate on Tutoplast® processed 
allografts 
CLSM revealed an elongated and spindle-like morphology of MSCs with a high cell 
density on SPAs and TPAs. 
DNA quantification to monitor cell adhesion and proliferation on the different grafts in 
a quantitative manner indicated the best MSC growth and proliferation on TPAs. These 
data were further supported by the MTS data for the TPA extracts indicating a good 
biocompatibility and viability levels close to the controls, as well as by the 
morphological assessment as described above. Further DNA quantification 
demonstrated that the initial adhesion was similar for all tested constructs so that the 
good cell growth on TPAs might not be explained by differences in initial cell adhesion 
or technical issues associated with the seeding procedure. 
 
4.3.2 Nitrogen levels as an indicator for organic material in Tutoplast® 
processed allografts and sonication-based processed allografts 
In this context, EDX analysis of bone grafts indicated in TPAs the highest value for 
nitrogen and conversely the lowest Ca/N ratios, followed by SPAs. Human bone is 
composed of a mineral phase (hydroxyapatite), an organic phase (mainly collagen type 
I) and water [96]. A high At% of nitrogen, ubiquitous in organic compounds, might 
correlate with a high amount of collagen [132] in TPAs and SPAs. MSCs, at the same 
time, readily adhere to collagen type I [133]. This in turn could explain superior 




4.3.3 Mesenchymal stem cell functionality of Bio-Oss® processed 
xenografts  
BPXs displayed the highest At% of calcium and phosphorous. Yet, Ca/P ratios were 
similar for all grafts and did not differ significantly. Shih et al. showed that calcium 
phosphate rich bone grafts can induce osteogenesis via a phosphate-adenosine 
signaling pathway [106]. It is interesting to note that while BPXs showed the highest 
At% of calcium and phosphorous, they also demonstrated the highest tentative, yet 
non-significant increase in ALP activity. Additionally, quantification of mineralization by 
Alizarin Red S showed tentative (DNA normalized) respectively significant (not 
normalized) increase potentially associated with osteoinductive properties of calcium 
rich BPXs. Accordingly, BPXs showed high background values in Alizarin Red S 
assays. While this further substantiates the results from EDX spectroscopy, depicting 
BPXs as the grafts with the highest amount of Ca (Figure 5A), it also limits to some 
extent the interpretability of results on mineralization due to these high background 
levels despite subtraction. 
 
4.4 Osteogenic activity 
Biomineralization and hydroxyapatite deposition is well known to depend on ALP 
activity as it provides phosphates during these processes [93,95]. Furthermore, ALP 
is amongst the early markers of osteoblast differentiation which is highly prominent in 
the starting phase of the mineralization process [134,135] but undergoes a 
downregulation when mineralization progresses. Accordingly, the significant decrease 
of ALP activity in TPAs, along with the increase in mineralization (non-normalized 
data), reflects such a typical marker profile widely described for osteogenic 
differentiation of MSCs and further underlines the impact of TPAs on MSC functionality. 
 
5. Summary 
The outcome of this study shows a higher efficacy in decellularization for sonication-
based processed allografts (SPAs) over chemically processed allografts (CPAs) based 
on DNA quantification, histological and scanning electron microscopy (SEM) 
evaluation. Moreover, the decellularization efficacy of SPAs was comparable to two 
commercial grafts, Tutoplast® processed allografts (TPAs) and Bio-Oss® processed 
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xenografts (BPXs), used as additional reference, also in terms of commercially 
standardized products. Biocompatibility assessment based on extracts derived from 
decellularized grafts showed a decrease in mesenchymal stem cell (MSC) viability for 
SPAs and CPAs, as well as for the commercially available BPXs. In contrast, 
biocompatibility was not impaired for TPAs, which also showed a better performance 
after reseeding with MSCs as indicated by confocal laser scanning microscopy (CSLM) 
and DNA assessment in order to monitor cellular proliferation. Here, a significant 
increase in DNA throughout a two-week time frame could be shown. BPXs induced a 
tentative increase in alkaline phosphatase (ALP) activity and mineralization in MSCs 
potentially associated with the high calcium content. Even though SPAs extracts 
showed a noticeable reduction of in vitro biocompatibility, results after reseeding with 
MSCs were comparable to commercially available grafts used in this study. 
Nevertheless, in this present study, TPAs combined the best in vitro biocompatibility 






6. Supplemental Material 
 
Supplemental figure 1. Alizarin Red S quantification of un-seeded sonication-based processed 
allografts, Tutoplast processed allografts and Bio-Oss processed xenografts as background. 
Background values of Alizarin Red S quantification were obtained by staining un-seeded grafts 
with Alizarin Red S solution and consecutively extracting and photocolorimetrically measuring 
the Alizarin Red S that attached to the un-seeded grafts. Bio-Oss processed xenografts show 
the highest values, differing significantly to all other grafts. Tutoplast processed allografts on 
the other hand, display the lowest values. Statistics are based on Tukey’s multiple comparison 















1.  United States Bone and Joint Initiative. The Burden of Musculoskeletal Diseases 
in the United States (BMUS), (Third Edition) [Internet]. Rosemont, IL ; [cited 15 
February 2019],                                
Available from: https://www.boneandjointburden.org/resources/archives 
2.  Curtis EM, van der Velde R, Moon RJ, van den Bergh JP, Geusens P, de Vries 
F, et al. Epidemiology of fractures in the United Kingdom 1988-2012: Variation 
with age, sex, geography, ethnicity and socioeconomic status. Bone. 
2016/03/13. 2016;87:19–26.  
3.  Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011/04/15. 
2011;42(6):551–5.  
4.  Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. 
Nat Rev Rheumatol. 2014/10/01. 2015;11(1):45–54.  
5.  Wiese A, Pape HC. Bone defects caused by high-energy injuries, bone loss, 
infected nonunions, and nonunions. Orthop Clin North Am. 2009/11/26. 
2010;41(1):1–4, table of contents.  
6.  Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. 
Clin Orthop Relat Res. 2000/02/29. 2000;(371):10–27.  
7.  Cypher TJ, Grossman JP. Biological principles of bone graft healing. J Foot 
Ankle Surg. 1996/09/01. 1996;35(5):413–7.  
8.  Homma Y, Zimmermann G, Hernigou P. Cellular therapies for the treatment of 
non-union: the past, present and future. Injury. 2013/02/13. 2013;44 Suppl 
1:S46-9.  
9.  Delloye C, Cornu O, Druez V, Barbier O. Bone allografts: What they can offer 
and what they cannot. J Bone Jt Surg (British Vol. 2007/06/02. 2007;89(5):574–
9.  
10.  Campana V, Milano G, Pagano E, Barba M, Cicione C, Salonna G, et al. Bone 
substitutes in orthopaedic surgery: from basic science to clinical practice. J Mater 
Sci Mater Med. 2014/05/29. 2014;25(10):2445–61.  
11.  Deijkers RL, Bouma GJ, van der Meer-Prins EM, Huysmans PE, Taminiau AH, 
Claas FH. Human bone allografts can induce T cells with high affinity for donor 
antigens. J Bone Jt Surg (British Vol. 2000/06/29. 1999;81(3):538–44.  
12.  Griesemer A, Yamada K, Sykes M. Xenotransplantation: immunological hurdles 
and progress toward tolerance. Immunol Rev. 2014/02/13. 2014;258(1):241–58.  
13.  Smith CA, Board TN, Rooney P, Eagle MJ, Richardson SM, Hoyland JA. Human 
decellularized bone scaffolds from aged donors show improved osteoinductive 
capacity compared to young donor bone. PLoS One. 2017/05/16. 
2017;12(5):e0177416.  
14.  Saulacic N, Bosshardt DD, Jensen SS, Miron RJ, Gruber R, Buser D. Impact of 
bone graft harvesting techniques on bone formation and graft resorption: a 
histomorphometric study in the mandibles of minipigs. Clin Oral Implants Res. 
 48 
2014/02/20. 2015;26(4):383–91.  
15.  do Desterro Fde P, Sader MS, Soares GD, Vidigal  Jr. GM. Can inorganic bovine 
bone grafts present distinct properties? Braz Dent J. 2014/09/25. 
2014;25(4):282–8.  
16.  Boyce T, Edwards J, Scarborough N. Allograft bone. The influence of processing 
on safety and performance. Orthop Clin North Am. 1999/09/03. 1999;30(4):571–
81.  
17.  Worth A, Mucalo M, Horne G, Bruce W, Burbidge H. The evaluation of processed 
cancellous bovine bone as a bone graft substitute. Clin Oral Implants Res. 
2005/05/10. 2005;16(3):379–86.  
18.  Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends 
and future prospective. Biosci Rep. 2015/03/24. 2015;35(2).  
19.  Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast 
colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell 
Tissue Kinet. 1970/10/01. 1970;3(4):393–403.  
20.  Friedenstein AJ, Piatetzky  II S, Petrakova K V. Osteogenesis in transplants of 
bone marrow cells. J Embryol Exp Morphol. 1966/12/01. 1966;16(3):381–90.  
21.  McDaniel JS, Antebi B, Pilia M, Hurtgen BJ, Belenkiy S, Necsoiu C, et al. 
Quantitative Assessment of Optimal Bone Marrow Site for the Isolation of 
Porcine Mesenchymal Stem Cells. Stem Cells Int. 2017/05/26. 
2017;2017:1836960.  
22.  Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. 
Comparative characteristics of mesenchymal stem cells from human bone 
marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005/11/03. 
2005;33(11):1402–16.  
23.  Zhang X, Yang M, Lin L, Chen P, Ma KT, Zhou CY, et al. Runx2 overexpression 
enhances osteoblastic differentiation and mineralization in adipose--derived 
stem cells in vitro and in vivo. Calcif Tissue Int. 2006/09/14. 2006;79(3):169–78.  
24.  Ab Kadir R, Zainal Ariffin SH, Megat Abdul Wahab R, Kermani S, Senafi S. 
Characterization of mononucleated human peripheral blood cells. 
ScientificWorldJournal. 2012/06/06. 2012;2012:843843.  
25.  Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derived from dental 
tissues vs. those from other sources: their biology and role in regenerative 
medicine. J Dent Res. 2009/09/22. 2009;88(9):792–806.  
26.  Morito T, Muneta T, Hara K, Ju YJ, Mochizuki T, Makino H, et al. Synovial fluid-
derived mesenchymal stem cells increase after intra-articular ligament injury in 
humans. Rheumatol. 2008/04/09. 2008;47(8):1137–43.  
27.  In ’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, 
Willemze R, et al. Amniotic fluid as a novel source of mesenchymal stem cells 
for therapeutic transplantation. Blood. 2003/08/06. 2003;102(4):1548–9.  
28.  Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal 
stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 
2004/12/08. 2004;22(7):1330–7.  
 49 
29.  Raynaud CM, Maleki M, Lis R, Ahmed B, Al-Azwani I, Malek J, et al. 
Comprehensive characterization of mesenchymal stem cells from human 
placenta and fetal membrane and their response to osteoactivin stimulation. 
Stem Cells Int. 2012/06/16. 2012;2012:658356.  
30.  da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside 
in virtually all post-natal organs and tissues. J Cell Sci. 2006/05/11. 2006;119(Pt 
11):2204–13.  
31.  Yin Z, Guo J, Wu TY, Chen X, Xu LL, Lin SE, et al. Stepwise Differentiation of 
Mesenchymal Stem Cells Augments Tendon-Like Tissue Formation and Defect 
Repair In Vivo. Stem Cells Transl Med. 2016/06/10. 2016;5(8):1106–16.  
32.  Hodgson B, Mafi R, Mafi P, Khan. The Regulation of Differentiation of 
Mesenchymal Stem-cells into Skeletal Muscle: A Look at Signalling Molecules 
Involved in Myogenesis. Curr Stem Cell Res Ther. 2017/09/12. 2018;13(5):384–
407.  
33.  Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of adult mesenchymal 
stem cells applicable for musculoskeletal applications - a systematic review of 
the literature. Open Orthop J. 2011/09/03. 2011;5 Suppl 2:242–8.  
34.  Shi C. Recent progress toward understanding the physiological function of bone 
marrow mesenchymal stem cells. Immunology. 2012/02/11. 2012;136(2):133–8.  
35.  Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et 
al. Minimal criteria for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement. Cytotherapy. 
2006/08/23. 2006;8(4):315–7.  
36.  Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A 
randomized, double-blind, placebo-controlled, dose-escalation study of 
intravenous adult human mesenchymal stem cells (prochymal) after acute 
myocardial infarction. J Am Coll Cardiol. 2009/12/05. 2009;54(24):2277–86.  
37.  White IA, Sanina C, Balkan W, Hare JM. Mesenchymal Stem Cells in Cardiology. 
Methods Mol Biol. 2016/05/30. 2016;1416:55–87.  
38.  Morigi M, Benigni A, Remuzzi G, Imberti B. The regenerative potential of stem 
cells in acute renal failure. Cell Transpl. 2006/07/11. 2006;15 Suppl 1:S111-7.  
39.  Morigi M, Rota C, Remuzzi G. Mesenchymal Stem Cells in Kidney Repair. 
Methods Mol Biol. 2016/05/30. 2016;1416:89–107.  
40.  Xu P, Yang X. The Efficacy and Safety of Mesenchymal Stem Cell 
Transplantation for Spinal Cord Injury Patients: A Meta-Analysis and Systematic 
Review. Cell Transpl. 2018/10/27. 2019;28(1):36–46.  
41.  Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of insulin-producing cells 
from human bone marrow mesenchymal stem cells by genetic manipulation. 
Stem Cells. 2007/07/07. 2007;25(11):2837–44.  
42.  Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, et al. Infusion of mesenchymal stem 
cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel 
role in improving insulin sensitivity. Diabetes. 2012/05/24. 2012;61(6):1616–25.  
43.  Chahal J, Gomez-Aristizabal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio 
 50 
A, et al. Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with 
Osteoarthritis Results in Overall Improvement in Pain and Symptoms and 
Reduces Synovial Inflammation. Stem Cells Transl Med. 2019/04/10. 
2019;8(8):746–57.  
44.  Iijima H, Isho T, Kuroki H, Takahashi M, Aoyama T. Effectiveness of 
mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-
analysis toward the establishment of effective regenerative rehabilitation. NPJ 
Regen Med. 2018/09/25. 2018;3:15.  
45.  Bhumiratana S, Eton RE, Oungoulian SR, Wan LQ, Ateshian GA, Vunjak-
Novakovic G. Large, stratified, and mechanically functional human cartilage 
grown in vitro by mesenchymal condensation. Proc Natl Acad Sci U S A. 
2014/04/30. 2014;111(19):6940–5.  
46.  Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. 
Transplantability and therapeutic effects of bone marrow-derived mesenchymal 
cells in children with osteogenesis imperfecta. Nat Med. 1999/03/23. 
1999;5(3):309–13.  
47.  Zhao D, Cui D, Wang B, Tian F, Guo L, Yang L, et al. Treatment of early stage 
osteonecrosis of the femoral head with autologous implantation of bone marrow-
derived and cultured mesenchymal stem cells. Bone. 2011/11/19. 
2012;50(1):325–30.  
48.  Rackwitz L, Eden L, Reppenhagen S, Reichert JC, Jakob F, Walles H, et al. 
Stem cell- and growth factor-based regenerative therapies for avascular 
necrosis of the femoral head. Stem Cell Res Ther. 2012/02/24. 2012;3(1):7.  
49.  Ismail HD, Phedy P, Kholinne E, Djaja YP, Kusnadi Y, Merlina M, et al. 
Mesenchymal stem cell implantation in atrophic nonunion of the long bones: A 
translational study. Bone Jt Res. 2016/07/15. 2016;5(7):287–93.  
50.  Jin YZ, Lee JH. Mesenchymal Stem Cell Therapy for Bone Regeneration. Clin 
Orthop Surg. 2018/09/04. 2018;10(3):271–8.  
51.  Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, et al. Autologous 
bone marrow stromal cells loaded onto porous hydroxyapatite ceramic 
accelerate bone repair in critical-size defects of sheep long bones. J Biomed 
Mater Res. 1999/12/22. 2000;49(3):328–37.  
52.  Quarto R, Giannoni P. Bone Tissue Engineering: Past-Present-Future. Methods 
Mol Biol. 2016/05/30. 2016;1416:21–33.  
53.  Gjerde C, Mustafa K, Hellem S, Rojewski M, Gjengedal H, Yassin MA, et al. Cell 
therapy induced regeneration of severely atrophied mandibular bone in a clinical 
trial. Stem Cell Res Ther. 2018/08/11. 2018;9(1):213.  
54.  Mangano FG, Colombo M, Veronesi G, Caprioglio A, Mangano C. Mesenchymal 
stem cells in maxillary sinus augmentation: A systematic review with meta-
analysis. World J Stem Cells. 2015/08/05. 2015;7(6):976–91.  
55.  Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem 
cell-mediated immunosuppression occurs via concerted action of chemokines 
and nitric oxide. Cell Stem Cell. 2008/03/29. 2008;2(2):141–50.  
 51 
56.  Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological 
characteristics of human mesenchymal stem cells and multipotent adult 
progenitor cells. Immunol Cell Biol. 2013/01/09. 2013;91(1):32–9.  
57.  Campeau PM, Rafei M, Francois M, Birman E, Forner KA, Galipeau J. 
Mesenchymal stromal cells engineered to express erythropoietin induce anti-
erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2008/12/18. 
2009;17(2):369–72.  
58.  Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, et 
al. Direct imaging of immune rejection and memory induction by allogeneic 
mesenchymal stromal cells. Stem Cells. 2009/09/15. 2009;27(11):2865–74.  
59.  Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not 
immune privileged. Nat Biotechnol. 2014/02/25. 2014;32(3):252–60.  
60.  Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-
Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose 
mesenchymal stem cell transplantation. Dis Colon Rectum. 2005/06/04. 
2005;48(7):1416–23.  
61.  Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, 
Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple 
sclerosis patients? Report of a pilot study. Iran J Immunol. 2007/07/27. 
2007;4(1):50–7.  
62.  Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori 
JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell 
transplantation in patients with multiple sclerosis and amyotrophic lateral 
sclerosis. Arch Neurol. 2010/10/13. 2010;67(10):1187–94.  
63.  Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et 
al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host 
disease. Transplantation. 2006/05/30. 2006;81(10):1390–7.  
64.  Schell H, Duda GN, Peters A, Tsitsilonis S, Johnson KA, Schmidt-Bleek K. The 
haematoma and its role in bone healing. J Exp Orthop. 2017/02/09. 2017;4(1):5.  
65.  Kolar P, Gaber T, Perka C, Duda GN, Buttgereit F. Human early fracture 
hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res. 
2011/03/17. 2011;469(11):3118–26.  
66.  Dimitriou R, Tsiridis E, Giannoudis P V. Current concepts of molecular aspects 
of bone healing. Injury. 2005/08/17. 2005;36(12):1392–404.  
67.  Su P, Tian Y, Yang C, Ma X, Wang X, Pei J, et al. Mesenchymal Stem Cell 
Migration during Bone Formation and Bone Diseases Therapy. Int J Mol Sci. 
2018/08/12. 2018;19(8).  
68.  Wynn RF, Hart CA, Corradi-Perini C, O’Neill L, Evans CA, Wraith JE, et al. A 
small proportion of mesenchymal stem cells strongly expresses functionally 
active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 
2004/07/15. 2004;104(9):2643–5.  
69.  Kitaori T, Ito H, Schwarz EM, Tsutsumi R, Yoshitomi H, Oishi S, et al. Stromal 
cell-derived factor 1/CXCR4 signaling is critical for the recruitment of 
 52 
mesenchymal stem cells to the fracture site during skeletal repair in a mouse 
model. Arthritis Rheum. 2009/02/28. 2009;60(3):813–23.  
70.  Toupadakis CA, Wong A, Genetos DC, Chung DJ, Murugesh D, Anderson MJ, 
et al. Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 
signaling, alters fracture repair. J Orthop Res. 2012/05/18. 2012;30(11):1853–9.  
71.  Knight MN, Hankenson KD. Mesenchymal Stem Cells in Bone Regeneration. 
Adv Wound Care (New Rochelle). 2014/02/15. 2013;2(6):306–16.  
72.  Oh M, Nor JE. The Perivascular Niche and Self-Renewal of Stem Cells. Front 
Physiol. 2015/12/24. 2015;6:367.  
73.  Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular 
origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 
2008/09/13. 2008;3(3):301–13.  
74.  Sabatini F, Petecchia L, Tavian M, Jodon de Villeroche V, Rossi GA, Brouty-
Boye D. Human bronchial fibroblasts exhibit a mesenchymal stem cell 
phenotype and multilineage differentiating potentialities. Lab Invest. 2005/06/01. 
2005;85(8):962–71.  
75.  Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y. Bone marrow-derived 
osteoblast progenitor cells in circulating blood contribute to ectopic bone 
formation in mice. Biochem Biophys Res Commun. 2007/01/24. 
2007;354(2):453–8.  
76.  Wan C, He Q, Li G. Allogenic peripheral blood derived mesenchymal stem cells 
(MSCs) enhance bone regeneration in rabbit ulna critical-sized bone defect 
model. J Orthop Res. 2006/03/04. 2006;24(4):610–8.  
77.  Edderkaoui B. Potential Role of Chemokines in Fracture Repair. Front 
Endocrinol. 2017/03/18. 2017;8:39.  
78.  Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, 
et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 
induction of SDF-1. Nat Med. 2004/07/06. 2004;10(8):858–64.  
79.  Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, et al. Activation of 
the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. 
Proc Natl Acad Sci U S A. 2008/01/11. 2008;105(2):686–91.  
80.  Filipowska J, Tomaszewski KA, Niedzwiedzki L, Walocha JA, Niedzwiedzki T. 
The role of vasculature in bone development, regeneration and proper systemic 
functioning. Angiogenesis. 2017/02/15. 2017;20(3):291–302.  
81.  Ge Q, Zhang H, Hou J, Wan L, Cheng W, Wang X, et al. VEGF secreted by 
mesenchymal stem cells mediates the differentiation of endothelial progenitor 
cells into endothelial cells via paracrine mechanisms. Mol Med Rep. 2017/11/16. 
2018;17(1):1667–75.  
82.  Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, 
bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994/11/01. 
1994;56(3):283–94.  
83.  Chen Q, Shou P, Zheng C, Jiang M, Cao G, Yang Q, et al. Fate decision of 
mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 
 53 
2016/02/13. 2016;23(7):1128–39.  
84.  Coelho MJ, Fernandes MH. Human bone cell cultures in biocompatibility testing. 
Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on 
osteoblastic differentiation. Biomaterials. 2000/05/19. 2000;21(11):1095–102.  
85.  Kim CH, Cheng SL, Kim GS. Effects of dexamethasone on proliferation, activity, 
and cytokine secretion of normal human bone marrow stromal cells: possible 
mechanisms of glucocorticoid-induced bone loss. J Endocrinol. 1999/09/01. 
1999;162(3):371–9.  
86.  Bai Y, Li P, Yin G, Huang Z, Liao X, Chen X, et al. BMP-2, VEGF and bFGF 
synergistically promote the osteogenic differentiation of rat bone marrow-derived 
mesenchymal stem cells. Biotechnol Lett. 2012/11/13. 2013;35(3):301–8.  
87.  Li R, Liang L, Dou Y, Huang Z, Mo H, Wang Y, et al. Mechanical strain regulates 
osteogenic and adipogenic differentiation of bone marrow mesenchymal stem 
cells. Biomed Res Int. 2015/04/30. 2015;2015:873251.  
88.  Xu N, Liu H, Qu F, Fan J, Mao K, Yin Y, et al. Hypoxia inhibits the differentiation 
of mesenchymal stem cells into osteoblasts by activation of Notch signaling. Exp 
Mol Pathol. 2012/09/12. 2013;94(1):33–9.  
89.  Lee HH, Chang CC, Shieh MJ, Wang JP, Chen YT, Young TH, et al. Hypoxia 
enhances chondrogenesis and prevents terminal differentiation through 
PI3K/Akt/FoxO dependent anti-apoptotic effect. Sci Rep. 2013/09/18. 
2013;3:2683.  
90.  Frank O, Heim M, Jakob M, Barbero A, Schafer D, Bendik I, et al. Real-time 
quantitative RT-PCR analysis of human bone marrow stromal cells during 
osteogenic differentiation in vitro. J Cell Biochem. 2002/04/23. 2002;85(4):737–
46.  
91.  Vicari L, Calabrese G, Forte S, Giuffrida R, Colarossi C, Parrinello NL, et al. 
Potential Role of Activating Transcription Factor 5 during Osteogenesis. Stem 
Cells Int. 2016/01/16. 2016;2016:5282185.  
92.  Hanna H, Mir LM, Andre FM. In vitro osteoblastic differentiation of mesenchymal 
stem cells generates cell layers with distinct properties. Stem Cell Res Ther. 
2018/07/29. 2018;9(1):203.  
93.  Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin 
Biochem. 2014/06/27. 2014;29(3):269–78.  
94.  Mornet E. Hypophosphatasia: the mutations in the tissue-nonspecific alkaline 
phosphatase gene. Hum Mutat. 2000/03/29. 2000;15(4):309–15.  
95.  E Golub E, Boesze-Battaglia K. The role of alkaline phosphatase in 
mineralization. Vol. 18. 2007. 444–448 p.  
96.  Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic 
drug effects. Bonekey Rep. 2014/02/07. 2013;2:447.  
97.  Polo-Corrales L, Latorre-Esteves M, Ramirez-Vick JE. Scaffold design for bone 
regeneration. J Nanosci Nanotechnol. 2014/04/16. 2014;14(1):15–56.  
98.  Zou L, Luo Y, Chen M, Wang G, Ding M, Petersen CC, et al. A simple method 
for deriving functional MSCs and applied for osteogenesis in 3D scaffolds. Sci 
 54 
Rep. 2013/07/23. 2013;3:2243.  
99.  Oryan A, Baghaban Eslaminejad M, Kamali A, Hosseini S, Moshiri A, Baharvand 
H. Mesenchymal stem cells seeded onto tissue-engineered osteoinductive 
scaffolds enhance the healing process of critical-sized radial bone defects in rat. 
Cell Tissue Res. 2018/05/03. 2018;374(1):63–81.  
100.  Gao C, Harvey EJ, Chua M, Chen BP, Jiang F, Liu Y, et al. MSC-seeded dense 
collagen scaffolds with a bolus dose of VEGF promote healing of large bone 
defects. Eur Cell Mater. 2013/10/15. 2013;26:195–207; discussion 207.  
101.  Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, et al. 
Stem cells associated with macroporous bioceramics for long bone repair: 6- To 
7-year outcome of a pilot clinical study. Tissue Eng. 2007;13(5):947–55.  
102.  Giannotti S, Trombi L, Bottai V, Ghilardi M, D’Alessandro D, Danti S, et al. Use 
of Autologous Human mesenchymal Stromal Cell/Fibrin Clot Constructs in 
Upper Limb Non-Unions: Long-Term Assessment. PLoS One. 2013 Aug 30;8(8).  
103.  Jones EA, Giannoudis P V., Kouroupis D. Bone repair with skeletal stem cells: 
rationale, progress to date and clinical application. Therapeutic Advances in 
Musculoskeletal Disease. 2016.  
104.  Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally 
responsive therapeutics for regenerative medicine. Exp Mol Med. 2013/11/16. 
2013;45:e54.  
105.  Linero I, Chaparro O. Paracrine effect of mesenchymal stem cells derived from 
human adipose tissue in bone regeneration. PLoS One. 2014/09/10. 
2014;9(9):e107001.  
106.  Shih YR, Hwang Y, Phadke A, Kang H, Hwang NS, Caro EJ, et al. Calcium 
phosphate-bearing matrices induce osteogenic differentiation of stem cells 
through adenosine signaling. Proc Natl Acad Sci U S A. 2014/01/08. 
2014;111(3):990–5.  
107.  Seebach C, Schultheiss J, Wilhelm K, Frank J, Henrich D. Comparison of six 
bone-graft substitutes regarding to cell seeding efficiency, metabolism and 
growth behaviour of human mesenchymal stem cells (MSC) in vitro. Injury. 
2010/03/18. 2010;41(7):731–8.  
108.  Harris CT, Cooper LF. Comparison of bone graft matrices for human 
mesenchymal stem cell-directed osteogenesis. J Biomed Mater Res Part A. 
2004/02/27. 2004;68(4):747–55.  
109.  Mylonas D, Vidal MD, De Kok IJ, Moriarity JD, Cooper LF. Investigation of a 
thermoplastic polymeric carrier for bone tissue engineering using allogeneic 
mesenchymal stem cells in granular scaffolds. J Prosthodont. 2007/08/09. 
2007;16(6):421–30.  
110.  Williams DF. On the mechanisms of biocompatibility. Biomaterials. 2008/04/29. 
2008;29(20):2941–53.  
111.  Lin X, Chen J, Qiu P, Zhang Q, Wang S, Su M, et al. Biphasic hierarchical 
extracellular matrix scaffold for osteochondral defect regeneration. Osteoarthr 
Cartil. 2017/12/14. 2018;26(3):433–44.  
 55 
112.  Smith CA, Richardson SM, Eagle MJ, Rooney P, Board T, Hoyland JA. The use 
of a novel bone allograft wash process to generate a biocompatible, 
mechanically stable and osteoinductive biological scaffold for use in bone tissue 
engineering. J Tissue Eng Regen Med. 2014/06/20. 2015;9(5):595–604.  
113.  Vastel L, Meunier A, Siney H, Sedel L, Courpied JP. Effect of different 
sterilization processing methods on the mechanical properties of human 
cancellous bone allografts. Biomaterials. 2004/01/27. 2004;25(11):2105–10.  
114.  Wang F, Schmidt H, Pavleska D, Wermann T, Seekamp A, Fuchs S. Crude 
Fucoidan Extracts Impair Angiogenesis in Models Relevant for Bone 
Regeneration and Osteosarcoma via Reduction of VEGF and SDF-1. Mar Drugs. 
2017/06/21. 2017;15(6).  
115.  Kolbe M, Xiang Z, Dohle E, Tonak M, Kirkpatrick CJ, Fuchs S. Paracrine effects 
influenced by cell culture medium and consequences on microvessel-like 
structures in cocultures of mesenchymal stem cells and outgrowth endothelial 
cells. Tissue Eng Part A. 2011/05/03. 2011;17(17–18):2199–212.  
116.  Sundaram J, Mellein BR, Mitragotri S. An experimental and theoretical analysis 
of ultrasound-induced permeabilization of cell membranes. Biophys J. 
2003/04/30. 2003;84(5):3087–101.  
117.  Li D, Jiang S, Yin X, Chang JW, Ke J, Zhang C. Efficacy of Needle, Ultrasonic, 
and Endoactivator Irrigation and Photon-Induced Photoacoustic Streaming in 
Removing Calcium Hydroxide from the Main Canal and Isthmus: An In Vitro 
Micro-Computed Tomography and Scanning Electron Microscopy Study. 
Photomed Laser Surg. 2015/06/13. 2015;33(6):330–7.  
118.  Pong M, Umchid S, Guarino AJ, Lewin PA, Litniewski J, Nowicki A, et al. In vitro 
ultrasound-mediated leakage from phospholipid vesicles. Ultrasonics. 
2006/09/19. 2006;45(1–4):133–45.  
119.  Moon KN, Kim SG, Oh JS, Kim CS, Lim SC, Jeong MA. Evaluation of bone 
formation after grafting with deproteinized bovine bone and mineralized allogenic 
bone. Implant Dent. 2015/01/27. 2015;24(1):101–5.  
120.  Benke D, Olah A, Mohler H. Protein-chemical analysis of Bio-Oss bone 
substitute and evidence on its carbonate content. Biomaterials. 2001/04/20. 
2001;22(9):1005–12.  
121.  Lampl T, Crum JA, Davis TA, Milligan C, Del Gaizo Moore V. Isolation and 
functional analysis of mitochondria from cultured cells and mouse tissue. J Vis 
Exp. 2015/04/14. 2015;(97).  
122.  Lodish H  Zipursky SL, et al. BA. Molecular Cell Biology. 4th edition. In New York: 
W. H. Freeman; 2000.  
123.  Helmers S, Sharkey PF, McGuigan FX. Efficacy of irrigation for removal of 
particulate debris after cemented total knee arthroplasty. J Arthroplast. 
1999/09/04. 1999;14(5):549–52.  
124.  Mebarki M, Coquelin L, Layrolle P, Battaglia S, Tossou M, Hernigou P, et al. 
Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds 
promotes cell survival and bone formation. Acta Biomater. 2017/06/22. 
 56 
2017;59:94–107.  
125.  Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol. 
2000/01/14. 1999;19(6):350–64.  
126.  Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of 
cytochrome c. Biochim Biophys Acta. 1998/08/26. 1998;1366(1–2):139–49.  
127.  Bernhardt A, Lode A, Peters F, Gelinsky M. Novel ceramic bone replacement 
material Osbone(R) in a comparative in vitro study with osteoblasts. Clin Oral 
Implants Res. 2010/11/04. 2011;22(6):651–7.  
128.  Liu Q, Douglas T, Zamponi C, Becker ST, Sherry E, Sivananthan S, et al. 
Comparison of in vitro biocompatibility of NanoBone((R)) and BioOss((R)) for 
human osteoblasts. Clin Oral Implants Res. 2011/10/12. 2011;22(11):1259–64.  
129.  Jin Y, Liu X, Liu H, Chen S, Gao C, Ge K, et al. Oxidative stress-induced 
apoptosis of osteoblastic MC3T3-E1 cells by hydroxyapatite nanoparticles 
through lysosomal and mitochondrial pathways. RSC Adv. 2017;7(21):13010–8.  
130.  Wiltfang J, Rohnen M, Egberts JH, Lutzen U, Wieker H, Acil Y, et al. Man as a 
Living Bioreactor: Prefabrication of a Custom Vascularized Bone Graft in the 
Gastrocolic Omentum. Tissue Eng Part C Methods. 2016/06/19. 
2016;22(8):740–6.  
131.  Traini T, Degidi M, Sammons R, Stanley P, Piattelli A. Histologic and elemental 
microanalytical study of anorganic bovine bone substitution following sinus floor 
augmentation in humans. J Periodontol. 2008/07/04. 2008;79(7):1232–40.  
132.  Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 
2009/04/07. 2009;78:929–58.  
133.  Somaiah C, Kumar A, Mawrie D, Sharma A, Patil SD, Bhattacharyya J, et al. 
Collagen Promotes Higher Adhesion, Survival and Proliferation of Mesenchymal 
Stem Cells. PLoS One. 2015/12/15. 2015;10(12):e0145068.  
134.  Rutkovskiy A, Stenslokken KO, Vaage IJ. Osteoblast Differentiation at a Glance. 
Med Sci Monit Basic Res. 2016/09/27. 2016;22:95–106.  
135.  Huang W, Yang S, Shao J, Li YP. Signaling and transcriptional regulation in 













Comparison of different grafts and processing methods in relation to mesenchymal 
stem cell usage. Rasch A, Naujokat H, Wang F, Seekamp A, Klüter T, Fuchs S, (2018) 
Life Sciences Student Conference Kiel 2018, Kiel Germany, Poster 
 
 
Rasch, A., Naujokat, H., Wang, F., Seekamp, A., Fuchs, S., & Klüter, T. (2019). 
Evaluation of bone allograft processing methods: Impact on decellularization efficacy, 




Evaluation of bone allograft processing methods: Impact on decellularization efficacy, 
biocompatibility and mesenchymal stem cell functionality. Rasch A, Naujokat H, Wang 
F, Seekamp A, Klüter T, Fuchs S, (2019) European Orthopaedic Research Society, 
Annual Meeting EORS 2019, Maastricht Netherlands, Oral Presentation 
 
 
Klüter, T., Hassan, R., Rasch, A., Naujokat, H., Wang, F., Behrendt, P., Lippross, S., 
Gerdesmeyer, L., Eglin, D., Seekamp, A., & Fuchs, S. (2020). An Ex Vivo Bone 
Defect Model to Evaluate Bone Substitutes and Associated Bone Regeneration 




I am thankful to Kieler Ärzteverein e.V. (Association of medical doctors in Kiel, 
Germany) for granting a travel scholarship for the purpose of visiting the Annual 
Meeting 2019 of the European Orthopaedic Research Society. On this occasion, 
“Evaluierung von Knochen-Allograft-Dezellularisationsmethoden zur Nutzung in 
Verbindung mit Mesenchymalen Stammzellen (MSCs)” was presented at the Annual 
Meeting of the Kieler Ärzteverein e.V.  
 
 58 
9. List of Materials 
9.1. Instruments 
Instrument Model Manufacturer 
Bandsaw  Metabo BAS Metabo, Nur̈tingen, 
Germany 
Beakers DURAN SCHOTT, Mitterteich, 
Germany 








CASY CASY TT OLS, Bremen, 
Germany 
Centrifuge Biofuge primo R Heraeus, Hanau, 
Germany 
Multifuge 3 S-R Heraeus, Hanau, 
Germany 
Confocal laser scanning 
microscopy 
LSM 510 Meta Zeiss, Oberkochen, 
Germany 




Cryotank Locator 4 plus Thermo Scientific, 
Marietta OH, USA 
Dremel drilling machine Dremel 3000 Dremel, Mt. Prospect, 
USA 
Epi-fluorescent microscope EVOS FL Auto 
2 
Life Technologies, 
Grand Island, USA 




Fridge (4°C) Profi line LIEBEHERR, Austria 





Freezer (-80°C) HERA freeze Heraeus, Hanau, 
Germany 
Fumehood Köttermann Köttermann, Uetze, 
Germany 
Graphpad Prism 7 Graphpad 
software 
GraphPad Software, 
Inc., La Jolla, CA, USA 
Grinding machine DP-U4 Struers, Erkrath, 
Germany 
High precision bandsaw Exakt 312 Exakt, Norderstedt, 
Germany 
High precision grinding machine Exakt 400 CS Exakt, Norderstedt, 
Germany 
Incubator BBD6220 & 




Laminar flow bench HERA safe Heraeus, Hanau, 
Germany 
Light microscope Axiovert 25 Zeiss, Oberkochen, 
Germany 
Luer forceps Luer Aesculap, Tuttlingen, 
Germany 
Microcentrifuge 3722L Fisher Scientific 
220VAC ROTH 
Orbital shaker Swip Edmund Bühler, 
Germany 
Pipette aid Pipetus HIRSCHMANN 
LABORGERÄTE 
Roller mixer SRT9 Stuart, Staffordshire, 
UK 
Scanning electron microscope 
(SEM) 





Sonicator MSE MSE, London, UK 















Vaccum pump AC500 HLC, Bovenden, 
Germany 





Bohemia, NY, USA 
Waterbath 1004 GFL, Burgwedel, 
Germany 




24-well-plates lid, sterile TPP, Trasadingen, Switzerland 
48-well-plates lid, sterile Falcon, corning NY, USA 
96-well-plates lid, sterile Sarstedt, Nümbrecht, Germany 
96-well-plates, F, Trans Greiner bio-one, Frickenhausen, 
Germany 
Aluminum foil Universal, Düsseldorf, Germany 
Carbon adhesive discs Agar Scientific, Stansted, UK 
Cell scrapers Sarstedt, Nümbrecht, Germany 
Cell Strainers 40 µm Nylon Falcon, Durham, USA 
Centrifuge Tubes (15mL, 50mL) Sarstedt, Nümbrecht, Germany 
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Filter 0.2 µm non-pyrogenic Sarstedt, Nümbrecht, Germany 
Microtubes (500µL, 1.5mL, 2mL) Sarstedt, Nümbrecht, Germany 
Needles 20G×1 ½”, Sterican® B.BRAUN, Melsungen, Germany 
Pasteur pipettes Assistant, Germany 
pH-indicator paper pH1-14 Merck, Darmstadt, Germany 
Pipette tips (10, 200, 1000µL) Sarstedt, Nümbrecht, Germany 
Serological Pipettes 
(5mL, 12mL and 25mL) 
Sarstedt, Nümbrecht, Germany 
Specimen-tables Agar Scientific, Stansted, UK 
Sterile surgical gloves  CardinalHealth, Dublin, OH, USA 
Syringe (5mL, 10mL, 20mL) BD, Madrid, Spain 
Tissue culture flasks vent. Cap 
(T25, T75, T175) 




Alizarin Red S Stain Solution Millipore, Billerica, USA 
Accutase® Biowest, Nuaillé, France 
Ascorbic acid Sigma-Aldrich, Darmstadt, Germany 
2,2′-Azobis(2-methylpropionitrile) Merck, Darmstadt, Germany 
β-Glycerophosphate Sigma-Aldrich, St. Louis, MO, USA 
Bio-Oss® Geistlich, Wolhusen, Switzerland 
Biocidal WAK Chemie Medical, Steinbach, 
Germany 
Bovine serum albumin (BSA) Millipore, Kankakee, USA 
Calcein AM fluorescent dye BD Biosciences, Bedford, USA 
Cell Tracker Invitrogen, Eugene, USA 
Collagen type I (rat tail) Corning, Bedford, MA, USA 
Cetylpyridinium chloride (CPC) Roth, Karlsruhe, Germany 
Cyproby FRESENIUS KABI, Bad Homburg, 
Germany 
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Dulbecco’s Medium Essential Medium 
(DMEM)/Ham F-12 1:1 
Biochrom, Berlin, Germany 
Dexamethasone Sigma-Aldrich, St. Louis, MO, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, MO, USA 
Ethylendiaminetetraacetat (EDTA) SERVA, Heidelberg, Germany 
Ethanol Merck, Darmstadt, Germany 
Fetal bovine serum (FBS) Sigma, Taufkirchen, Germany 
Fibronectin Millipore, Temecula, CA, USA 
Formic acid  Merck, Darmstadt, Germany 
Fungizone Biozol, Eching, Germany 
Glutaraldehyde Sigma-Aldrich, Darmstadt, Germany 
Hexamethyldisilazane ThermoFisher, Kandel, Germany 
Hoechst Sigma-Aldrich, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Medium 199 GlutaMAXTM Gibco, Darmstadt, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
Methyl methacrylate (MMA) Fluka, Neu-Ulm, Germany 
Nonylphenol-polyethylene glycol 
acetate 
Walter-CMP, Kiel, Germany 
Nuclease-free water Ambion, Carlsbad, CA, USA 
Paraformaldehyde solution in PBS 
4% 
Morphisto, Frankfurt am Main, 
Germany 
Phalloidin-TRITC Sigma-Aldrich, St. Louis, MO, USA 
Penicillin/ streptomycin (Pen/Strep) Biochrom, Berlin, Germany 
Phosphate buffered saline (PBS) 
10× 
Gibco, Darmstadt, Germany 
Phthalic acid butyl ester Merck, Darmstadt, Germany 
SDS Sigma-Aldrich, St. Louis, MO, USA 
Toluidine blue staining solution Merck, Darmstadt, Germany 
Triton® X-100 Sigma-Aldrich, Taufkirchen, Germany 
Tutoplast® RTI Surgical, Alachua, FL, USA 
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Water Ampuwa® FRESENIUS KABI, Bad Homburg, 
Germany 
 
9.4 Buffers and media 
Buffer Composition 
Buffy-coat buffer 2mM EDTA, 0.5% (v/v) FBS in PBS 
Tissue buffer 15% (v/v) FBS, 1% Pen/Strep, 1% 
Fungizone and 1% Cyproby in Medium 
199 GlutaMAXTM 
MSC growth medium 10% FBS 10% (v/v) FBS, 1% Pen/Strep in 
DMEM/Ham’s F-12 1:1 
MSC growth medium 20% FBS 20% (v/v) FBS, 1% Pen/Strep in 
DMEM/Ham’s F-12 1:1 
Osteogenic differentiation medium 
(ODM) 
10% (v/v) FBS, 1% (v/v) Pen/Strep, 10 
mM β-glycerol phosphate, 0,1 μM 
dexamethasone and 50 μM ascorbic 




Alkaline phosphatase assay kit Abcam, Cambridge, UK 
CellTiter 96® AQueous One 
Solution Cell Proliferation Assay 
Promega, Madison, USA 
Quant-iT PicoGreen dsDNA assay 
kit 
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